[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 295
1. Santoro R, Carboni F, Lepiane P, Ettorre GM, Santoro E: Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg; 2007 Jun;94(6):737-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In the younger group there were significantly more women (57 versus 36.3 per cent; P = 0.004), Laurén diffuse-type carcinomas (73 versus 42.7 per cent; P < 0.001), N2-3 lymph node metastases (59 versus 38.9 per cent; P = 0.005), stage IV disease (49 versus 35.7 per cent; P = 0.085) and resections that were non-curative (36 versus 18.5 per cent; P = 0.007) than in the older patients.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrectomy / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 British Journal of Surgery Society Ltd.
  • (PMID = 17330827.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Kim Y, Roh S, Park JY, Kim Y, Cho DH, Kim JC: Differential expression of the LOX family genes in human colorectal adenocarcinomas. Oncol Rep; 2009 Oct;22(4):799-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paradoxical roles of the LOX family members have been reported in various neoplastic tissues as tumor suppressors or promoters depending on tumor status and type.
  • The expression of the LOX family genes was not statistically associated with tumor location, stage, growth type, or differentiation status.
  • Additionally, expression of LOX, but not the other LOX family genes, was significantly upregulated in patients with a diffuse cytoplasmic expression pattern of CEA, indicating that LOX upregulation may be associated with increased invasiveness and metastatic potential in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Amino Acid Oxidoreductases / genetics. Colorectal Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19724858.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 1.4.- / Amino Acid Oxidoreductases; EC 1.4.3.- / LOXL1 protein, human; EC 1.4.3.- / LOXL2 protein, human; EC 1.4.3.- / LOXL3 protein, human; EC 1.4.3.- / LOXL4 protein, human
  •  go-up   go-down


3. Gopalan A, Sharp DS, Fine SW, Tickoo SK, Herr HW, Reuter VE, Olgac S: Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol; 2009 May;33(5):659-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation.
  • Thirteen cases were pure adenocarcinoma, not otherwise specified, 9 were enteric type adenocarcinoma, and 2 were adenocarcinoma with focal components of lymphoepithelioma-like carcinoma and urothelial carcinoma with cytoplasmic clearing.
  • Urachal remnants were identified in 15 cases: the urachal epithelium was benign urothelial-type in 6 cases and showed adenomatous changes in 9.
  • The overlying bladder urothelium was colonized by adenocarcinoma in 3 cases.
  • CONCLUSIONS: Pathologic stage is an important prognostic factor in urachal carcinoma.
  • Surface urothelial involvement by carcinoma and presence of cystitis cystica/glandularis do not necessarily exclude the diagnosis of urachal carcinoma.
  • Immunostains do not unequivocally discriminate a urachal from a colorectal carcinoma, but diffuse positivity for 34BE12 would support, and diffuse nuclear immunoreactivity for beta-catenin would militate against, a diagnosis of urachal carcinoma.
  • The type of surgery performed may have an effect on local recurrence despite negative margins of resection.
  • [MeSH-major] Carcinoma / pathology. Urachus / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / pathology. Chemotherapy, Adjuvant. Cystectomy. Cystitis / pathology. Databases as Topic. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Treatment Outcome. Umbilicus / surgery. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1380-7 [11684954.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2434-40 [17932892.001]
  • [Cites] J Urol. 2003 Apr;169(4):1295-8 [12629346.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):456-9 [15043458.001]
  • [Cites] J Urol. 1982 Jan;127(1):40-2 [7057501.001]
  • [Cites] Urology. 1983 Apr;21(4):360-6 [6836822.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • [Cites] Urol Res. 1983;11(5):235-8 [6659216.001]
  • [Cites] Urology. 1985 Sep;26(3):218-21 [4035835.001]
  • [Cites] J Urol. 1986 Jun;135(6):1240-4 [3712579.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2165-72 [1706216.001]
  • [Cites] J Urol. 1994 Feb;151(2):365-6 [8283526.001]
  • [Cites] Hum Pathol. 1996 Mar;27(3):240-7 [8600037.001]
  • [Cites] Cancer. 1955 Jul-Aug;8(4):741-58 [13240656.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):69-87 [16512600.001]
  • [Cites] J Urol. 2006 Jun;175(6):2042-7; discussion 2047 [16697798.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):712-20 [16826585.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):721-8 [16826584.001]
  • [Cites] J Urol. 2007 Jul;178(1):74-8; discussion 78 [17499279.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • (PMID = 19252435.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS627175; NLM/ PMC4225778
  •  go-up   go-down


Advertisement
4. Maezato K, Nishimaki T, Oshiro M, Yamashiro T, Sasaki H, Sashida Y: Signet-ring cell carcinoma of the esophagus associated with Barrett's epithelium: report of a case. Surg Today; 2007;37(12):1096-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell carcinoma of the esophagus associated with Barrett's epithelium: report of a case.
  • We herein report a case of infiltrative esophageal signet-ring cell carcinoma resembling gastric signet-ring cell carcinoma.
  • Grossly, the tumor was a diffusely infiltrative carcinoma involving the lower esophagus measuring 11 cm in diameter.
  • Histologically, the tumor was signet-ring cell carcinoma covered with normal squamous epithelium.
  • However, the most superficial part of the tumor center contained a region of Barrett's mucosa with incomplete-type intestinal metaplasia and a well-differentiated adenocarcinoma component with goblet cells.
  • The expression of cytokeratins 7 and 20 also indicated that both the Barrett's mucosa and the signet-ring cell carcinoma had an esophageal origin.
  • Esophageal signet-ring cell carcinoma with diffuse infiltrative growth is quite rare, and may need a special treatment strategy because of its highly aggressive behavior and poor treatment outcome.
  • [MeSH-major] Barrett Esophagus / complications. Carcinoma, Signet Ring Cell / pathology. Esophageal Neoplasms / pathology


5. Carvalho R, Milne AN, Polak M, Offerhaus GJ, Weterman MA: A novel region of amplification at 11p12-13 in gastric cancer, revealed by representational difference analysis, is associated with overexpression of CD44v6, especially in early-onset gastric carcinomas. Genes Chromosomes Cancer; 2006 Oct;45(10):967-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffuse-type gastric carcinomas (GCs) are often difficult to characterize because of contamination of tumor samples by surrounding normal tissue.
  • In this study, we used representational difference analysis to pinpoint genomic amplifications occurring in diffuse-type GCs.
  • These amplifications were confirmed using Southern blot analysis and occurred in 3/16 and 6/15 diffuse-type GCs, respectively.
  • We confirmed that overexpression of isoform CD44v6 was correlated with amplification at 11p12-13 in 11/12 diffuse-type GCs.
  • Since diffuse-type GCs occur more frequently in early-onset gastric carcinomas (EOGCs, presented at 45 years of age or younger) than in "conventional" GCs, and the tumors carrying the original amplifications were EOGCs, we investigated overexpression of CD44v6 in 107 EOGCs and 88 conventional GCs using tissue microarrays.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, CD44 / genetics. Chromosomes, Human, Pair 11 / genetics. Gene Amplification. Gene Expression Regulation, Neoplastic / physiology. Glycoproteins / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16868940.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44v6 antigen; 0 / Glycoproteins
  •  go-up   go-down


6. Tanigawa N, Nomura E, Lee SW, Kaminishi M, Sugiyama M, Aikou T, Kitajima M, Society for the Study of Postoperative Morbidity after Gastrectomy: Current state of gastric stump carcinoma in Japan: based on the results of a nationwide survey. World J Surg; 2010 Jul;34(7):1540-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current state of gastric stump carcinoma in Japan: based on the results of a nationwide survey.
  • BACKGROUND: Carcinoma of the gastric remnant after partial gastrectomy for benign disease or cancer is unusual but an important cancer model.
  • The Japanese Society for the Study of Postoperative Morbidity after Gastrectomy (JSSPMG) performed a nationwide questionnaire survey to understand the current state of gastric stump carcinoma in Japan.
  • METHODS: In the questionnaire survey of November 2008, gastric stump carcinoma was defined as an adenocarcinoma of the stomach occurring 10 years or more after Billroth I or Billroth II gastrectomy for benign condition or cancer disease.
  • The survey was conducted at the request of reports on five or more patients with gastric stump carcinoma for each institution.
  • (3) Tumor histology of 72.4% of 304 stump carcinomas at an early stage was intestinal type adenocarcinoma, i.e., well or moderately differentiated adenocarcinoma, whereas it decreased to 42.2% at the locally advanced stage of 521 stump carcinomas (P = 0.0015), suggesting that stump carcinoma mostly may develop from intestinal type and change to diffuse type during the evolution to advanced stage cancers.
  • CONCLUSIONS: This large series of surveys suggest that there are two distinct biological plausibilities in the development of gastric stump carcinoma:.
  • [MeSH-major] Adenocarcinoma / epidemiology. Gastric Stump. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1971 Apr;102(4):260-5 [4928618.001]
  • [Cites] Cancer. 1972 Jan;29(1):205-9 [5007382.001]
  • [Cites] Am J Surg. 1976 Jul;132(1):26-31 [952334.001]
  • [Cites] Lancet. 1976 Nov 13;2(7994):1037-9 [62896.001]
  • [Cites] Lancet. 1980 Apr 5;1(8171):727-9 [6103154.001]
  • [Cites] World J Surg. 1981 Jul;5(4):595-605 [7324494.001]
  • [Cites] N Engl J Med. 1982 Aug 26;307(9):519-22 [7099223.001]
  • [Cites] Br J Surg. 1983 Jun;70(6):322-5 [6860906.001]
  • [Cites] Br J Surg. 1983 Sep;70(9):552-4 [6616162.001]
  • [Cites] N Engl J Med. 1983 Nov 17;309(20):1210-3 [6633569.001]
  • [Cites] Cancer Res. 1984 May;44(5):2208-12 [6713408.001]
  • [Cites] J Natl Cancer Inst. 1984 Jun;72(6):1431-5 [6587160.001]
  • [Cites] Clin Gastroenterol. 1984 May;13(2):569-600 [6378447.001]
  • [Cites] J Clin Pathol. 1984 Jul;37(7):748-54 [6747012.001]
  • [Cites] Lancet. 1986 Apr 26;1(8487):929-31 [2871238.001]
  • [Cites] Lancet. 1986 Aug 30;2(8505):502-5 [2875248.001]
  • [Cites] Jpn J Cancer Res. 1987 Apr;78(4):337-48 [3108214.001]
  • [Cites] N Engl J Med. 1988 Jul 28;319(4):195-200 [3393171.001]
  • [Cites] Int J Cancer. 1988 Sep 15;42(3):365-7 [3417364.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6486-9 [2145061.001]
  • [Cites] Langenbecks Arch Chir. 1991;376(1):16-22 [2034000.001]
  • [Cites] Gut. 1991 Jul;32(7):740-4 [1855679.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Carcinogenesis. 1992 Dec;13(12):2313-6 [1473239.001]
  • [Cites] J Natl Cancer Inst. 1993 Aug 18;85(16):1303-10 [8340942.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Mar;13 Suppl 1:3-11 [10209681.001]
  • [Cites] Ann Surg. 1956 Feb;143(2):173-9 [13292871.001]
  • [Cites] Gastric Cancer. 2006;9(2):51-66 [16767357.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):453-62 [18669424.001]
  • [Cites] Gastric Cancer. 2002;5(1):23-8 [12021856.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul;20 Suppl 1:85-9 [15298611.001]
  • (PMID = 20182716.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2895900
  • [Investigator] Katai H; Takashima S; Kinoshita T; Yamamura Y; Kunisaki T; Tajiri T; Takenaka A; Otsuji E; Fuji Y; Tsurumaru M; Ogawa K; Saito H; Ota T; Nagai H; Yamazaki Y; Kaminishi M; Takiyama W; Sakuramoto S; Sasaki M; Tanigawa N; Hirakawa K; Fujiya T; Fujii H; Iwasaka N; Ooi E; Matsubara Y; Matsushita T; Tatsumi M; Yamamoto Y; Arita T; Wakabayashi G; Takiguchi N; Kitamura M; Nagata N; Watanabe S; Kimura W; Bandai Y; Kasai S; Hishiyama T; Yamada T; Kitano S; Monden M; Takabatake T; Yoshikawa T; Maehara Y; Oshita H; Nashimoto A; Ishida H; Sasaki I; Ishikawa H; Tani T; Kurita H; Kumagai K; Kusano M; Furukawa H; Konishi F; Kondo Y; Nakada K; Yamamoto M; Iwasaki Y; Inada T; Arai K; Sunagawa M; Shimizu T; Tamiya Y; Tokunaga A; Takayama T; Ishida Y; Ninomiya M; Goto M; Uyama I; Naito H; Mochizuki H; Miyata N; Naito H; Oka M; Tsuji T; Miyashiro I; Aoki T; Kanematsu T; Morita T; Tanaka K; Monden T; Yamasaki Y; Takahashi M; Fujii Y; Shiozaki H; Sugiyama Y
  •  go-up   go-down


7. Cho YG, Song JH, Kim CJ, Nam SW, Yoo NJ, Lee JY, Park WS: Genetic and epigenetic analysis of the KLF4 gene in gastric cancer. APMIS; 2007 Jul;115(7):802-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutational analysis revealed one mutation of the KLF4 gene in a diffuse-type advanced gastric adenocarcinoma, but not in the gastric adenoma.
  • [MeSH-major] Adenocarcinoma / genetics. Epigenesis, Genetic. Gene Expression Regulation. Kruppel-Like Transcription Factors / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614846.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors
  •  go-up   go-down


8. Van Domselaar F, Correa D, Vaccaro C, Redal M, Van Domselaar R, Huntsman D, Kaurah P, Senz J, Lynch H: [Hereditary diffuse gastric cancer (HDGC): presentation of a family with a new mutation of the CDH1 gene]. Acta Gastroenterol Latinoam; 2007 Sep;37(3):158-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hereditary diffuse gastric cancer (HDGC): presentation of a family with a new mutation of the CDH1 gene].
  • [Transliterated title] Cáncer gástrico difuso hereditario (CGDH): presentación de una familia con una nueva mutación del gen CDH1.
  • CASE: 28 year-old woman who underwent gastrectomy for a diffuse type gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Cadherins / genetics. Mutation. Stomach Neoplasms / genetics


9. Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, Fujii C, Nomoto K, Mukaida N, Takano Y: Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol; 2008 Apr;134(4):481-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.
  • RESULTS: Pim-3 expression was enhanced in adenoma (64.6%) and metastasis sites of gastric carcinoma (73.0%), to a lesser degree in primary sites of gastric carcinoma (39.3%) when compared to non-cancerous mucosa (13.1%, p < 0.0001).
  • Pim-3 expression levels were higher in intestinal-type than diffuse-type gastric carcinoma (p = 0.018).
  • Furthermore, patients with Pim-3 positive gastric cancer, showed a lower cumulative survival rate than those with Pim-3 negative gastric cancer (p = 0.014) and Pim-3 positive was also identified as an independent prognostic factor for gastric carcinoma patients (p = 0.006).
  • CONCLUSIONS: Aberrant Pim-3 expression was involved in gastric adenoma-adenocarcinoma sequence and subsequent invasion and metastasis process in gastric cancer.
  • Distinct Pim-3 expression underlies the molecular mechanisms for the differentiation of intestinal-type and diffuse-type carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenoma / chemistry. Protein-Serine-Threonine Kinases / analysis. Proto-Oncogene Proteins / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1560-3 [14571786.001]
  • [Cites] J Surg Oncol. 2007 Aug 1;96(2):95-101 [17443727.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):209-18 [15540201.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):376-80 [15900596.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):201-5 [11756242.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):241-52 [15799824.001]
  • [Cites] Lung Cancer. 2006 Feb;51(2):181-91 [16324768.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):169-80 [8534865.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3579-83 [17094486.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):499-516 [12134615.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(11):3897-908 [12748291.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4536-44 [14982870.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):242-8 [15543611.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23 [16807756.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):321-8 [17270021.001]
  • [Cites] Pathol Int. 2003 Oct;53(10 ):659-66 [14516315.001]
  • [Cites] Eur J Cancer. 1999 Apr;35(4):647-51 [10492641.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):507-18 [14655756.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):16-26 [11197247.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):16535-43 [9632723.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40 [18091387.001]
  • [Cites] EMBO J. 1999 Jun 15;18(12):3359-69 [10369676.001]
  • [Cites] Cell Oncol. 2005;27(4):215-23 [16308470.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2618-24 [16200194.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6741-7 [16818649.001]
  • [Cites] Croat Med J. 2007 Apr;48(2):207-17 [17436385.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1371-8 [17088917.001]
  • [Cites] Hepatogastroenterology. 2006 Jul-Aug;53(70):484-90 [16995446.001]
  • (PMID = 17876606.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / PIM3 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


10. Moss SF, Lee JW, Sabo E, Rubin AK, Rommel J, Westley BR, May FE, Gao J, Meitner PA, Tavares R, Resnick MB: Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: influence of tumor histology and relationship to prognosis. Clin Cancer Res; 2008 Jul 1;14(13):4161-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Decreased GKN1 and GKN2 mRNA expression has been reported in gastric adenocarcinoma.
  • RESULTS: GKN1 was lost in 78% of diffuse and 42% of intestinal cancers (P < 0.0001, diffuse versus intestinal).
  • GKN2 expression was lost in 85% of diffuse and 54% of intestinal type cancers (P < 0.002).
  • Loss of either protein was associated with significantly worse outcome in intestinal-type tumors by univariate analysis; and GKN2 loss remained a predictor of poor outcome in multivariate analysis (P < 0.033).
  • CONCLUSIONS: Loss of GKN1 and GKN2 expression occurs frequently in gastric adenocarcinomas, especially in the diffuse subtype.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Int J Oncol. 2001 Oct;19(4):701-7 [11562744.001]
  • [Cites] Cell. 2002 Apr 5;109(1):113-24 [11955451.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1092-9 [12006524.001]
  • [Cites] Pathology. 2002 Jun;34(3):275-81 [12109791.001]
  • [Cites] Trends Biochem Sci. 2002 Jul;27(7):329-32 [12114016.001]
  • [Cites] Int J Mol Med. 2003 Jul;12(1):3-9 [12792801.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G332-43 [12851218.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):592-600 [12894247.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2003 Jul 10;83(13):1166-8 [12921637.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Sep;4(9):721-32 [14506475.001]
  • [Cites] IARC Sci Publ. 2004;(157):327-49 [15055305.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 11;101(19):7409-14 [15123808.001]
  • [Cites] J Pathol. 2004 Jul;203(3):789-97 [15221938.001]
  • [Cites] J Clin Pathol. 2004 Aug;57(8):861-6 [15280409.001]
  • [Cites] Lancet. 1975 Jul 12;2(7924):58-60 [49653.001]
  • [Cites] Gastroenterology. 1991 Jul;101(1):167-74 [2044906.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):677-82 [1911216.001]
  • [Cites] J Pathol. 1993 Dec;171(4):263-9 [8158455.001]
  • [Cites] Science. 1996 Oct 11;274(5285):259-62 [8824193.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Biochemistry. 2005 Jun 7;44(22):7967-75 [15924415.001]
  • [Cites] Dig Dis Sci. 2005 Jun;50(6):1078-86 [15986858.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):886-92 [16112005.001]
  • [Cites] Int J Oncol. 2005 Oct;27(4):997-1003 [16142316.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6472-8 [16166422.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(24):2910-5 [16374578.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii97-102 [16760303.001]
  • [Cites] Proteomics. 2006 Aug;6(15):4235-45 [16888721.001]
  • [Cites] Gut. 2006 Dec;55(12):1717-24 [16641130.001]
  • [Cites] Dig Liver Dis. 2007 Feb;39(2):122-9 [17092786.001]
  • [Cites] Gut. 2000 Mar;46(3):312-20 [10673290.001]
  • [Cites] Cancer Lett. 2000 Feb 28;149(1-2):125-34 [10737716.001]
  • [Cites] Jpn J Cancer Res. 2000 May;91(5):459-63 [10835488.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):691-8 [10982763.001]
  • [Cites] J Clin Invest. 2002 Jan;109(2):193-204 [11805131.001]
  • (PMID = 18593995.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR017695-057270; United States / NCI NIH HHS / CA / CA111533-02; United States / NCRR NIH HHS / RR / P20 RR017695; United States / NCRR NIH HHS / RR / RR017695-057270; United States / NCI NIH HHS / CA / R01CA111533; United States / NCRR NIH HHS / RR / P20RR17695; United States / NCI NIH HHS / CA / R01 CA111533-02; United States / NCI NIH HHS / CA / R01 CA111533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / GKN1 protein, human; 0 / GKN2 protein, human; 0 / Peptide Hormones
  • [Other-IDs] NLM/ NIHMS72349; NLM/ PMC2572195
  •  go-up   go-down


11. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS: Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology; 2009 Sep;137(3):824-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over 90% of lymphoepithelioma-like carcinomas were EBV positive, but only 15 studies reported any cases of this type; prevalence did not significantly differ between the more common diffuse (9.5%) [corrected] and intestinal (7.6%) [corrected] histologies.
  • [MeSH-minor] Adenocarcinoma / virology. Carcinoma / virology. Cardia / virology. Epstein-Barr Virus Infections / complications. Female. Gastric Stump. Humans. Male. Pyloric Antrum / virology. Sex Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Clin Cancer Res. 2005 Sep;24(3):379-85 [16270524.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6096-103 [16273633.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Dec;24(4):547-53 [16471317.001]
  • [Cites] World J Gastroenterol. 2006 Mar 28;12(12):1842-8 [16609989.001]
  • [Cites] J Med Microbiol. 2006 Jul;55(Pt 7):905-11 [16772418.001]
  • [Cites] Int J Epidemiol. 2006 Oct;35(5):1270-1 [16980313.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1031-8 [10833477.001]
  • [Cites] Pathol Int. 2000 Jun;50(6):486-92 [10886725.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):354-63 [10989635.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] Eur J Cancer Prev. 2001 Feb;10(1):69-75 [11263593.001]
  • [Cites] Jpn J Cancer Res. 2001 Sep;92(9):911-7 [11572757.001]
  • [Cites] Int J Cancer. 2001 Nov15;94(4):527-30 [11745439.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):702-4 [11875729.001]
  • [Cites] Scand J Gastroenterol. 2002 Jul;37(7):825-9 [12190097.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):669-75 [12194996.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):384-9 [12226826.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2008-9 [12242430.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] J Pathol. 2003 Apr;199(4):447-52 [12635135.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):478-80 [12683879.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):641-51 [12861059.001]
  • [Cites] Gastric Cancer. 2003;6(3):173-8 [14520531.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):664-70 [14966089.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1093-8 [15492798.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] IARC Sci Publ. 1978;(20):167-89 [215514.001]
  • [Cites] Arch Surg. 1982 Mar;117(3):294-7 [7065870.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Mod Pathol. 1990 May;3(3):377-80 [2163534.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5455-9 [8390666.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] Lab Invest. 1994 Jul;71(1):73-81 [8041121.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 [8090780.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1158-63 [7943537.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):695-8 [7962618.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):952-9 [8622698.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):174-81 [8607441.001]
  • [Cites] Histopathology. 1996 Feb;28(2):121-7 [8834519.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Jpn J Cancer Res. 1997 Mar;88(3):262-6 [9140110.001]
  • [Cites] Pathol Int. 1997 Jun;47(6):360-7 [9211523.001]
  • [Cites] BMJ. 1998 May 16;316(7143):1507-10 [9582144.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:47-373 [9612712.001]
  • [Cites] Oral Oncol. 1998 Jan;34(1):15-23 [9659515.001]
  • [Cites] Pathol Res Pract. 1998;194(10):705-11 [9820867.001]
  • [Cites] J Clin Pathol. 1998 Sep;51(9):662-6 [9930069.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1582-6 [10364028.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1214-9 [10370694.001]
  • [Cites] J Clin Gastroenterol. 1999 Jul;29(1):39-43 [10405229.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15730-5 [15498875.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Gut. 2007 Jul;56(7):918-25 [17317788.001]
  • [Cites] Gut. 2007 Dec;56(12):1671-7 [17627962.001]
  • [Cites] World J Gastroenterol. 2008 Feb 14;14(6):884-91 [18240345.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):195-201 [18271915.001]
  • [Cites] Aging Clin Exp Res. 2008 Apr;20(2):91-102 [18431075.001]
  • [Cites] Hepatogastroenterology. 2008 Jan-Feb;55(81):41-5 [18507075.001]
  • [Cites] Scand J Gastroenterol. 2008;43(6):669-74 [18569983.001]
  • [Cites] World J Gastroenterol. 2008 Jul 21;14(27):4347-51 [18666324.001]
  • [Cites] Int J Epidemiol. 2008 Oct;37(5):1158-60 [18832388.001]
  • [Cites] Gut. 2009 Jan;58(1):16-23 [18838486.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Gastroenterol. 2005 Jun;40(6):570-7 [16007390.001]
  • [ErratumIn] Gastroenterology. 2011 Mar;140(3):1109
  • (PMID = 19445939.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS424076; NLM/ PMC3513767
  •  go-up   go-down


12. Soini Y, Tommola S, Helin H, Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch; 2006 Jan;448(1):52-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype.
  • In this study expression of claudins 1, 3, 4 and 5 were studied in 118 cases of gastric carcinoma and compared with proliferation, apoptosis and E-cadherin expression.
  • Expression of all these claudins could be seen in gastric carcinoma, most prominently for claudin 4, and least expression was found for claudin 5.
  • All claudins showed significantly more expression in gastric carcinomas of intestinal type.
  • Claudin 3 expression had an association with a better prognosis of the patients, especially in the intestinal type.
  • The results show that expression of claudins 1, 3, 4 and 5 is lower in diffuse-type gastric carcinomas.
  • Possibly they play a role in determining the diffuse phenotype and loose cohesion of cells in diffuse type of gastric carcinoma in a similar manner as E-cadherin.
  • The loss of their expression does not clearly associate with poorer prognosis of the patients, except for claudin 3, where strong expression was associated with a better outcome of the patients, a feature especially related to intestinal-type tumours.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] J Cell Biol. 1992 Apr;117(2):415-25 [1373144.001]
  • [Cites] J Am Soc Nephrol. 2002 Apr;13(4):875-86 [11912246.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] J Cell Biol. 2000 Apr 3;149(1):13-6 [10747082.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Curr Opin Cell Biol. 2002 Oct;14(5):531-6 [12231346.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1620-6 [12459629.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1690-5 [8453643.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1531-6 [15619213.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] J Cell Biol. 1988 Oct;107(4):1575-87 [3049625.001]
  • [Cites] J Cell Sci. 2004 May 15;117(Pt 12):2435-47 [15159449.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G250-4 [10915631.001]
  • [Cites] Kidney Int. 2002 Aug;62(2):476-87 [12110008.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] J Mol Cell Cardiol. 2005 Feb;38(2):323-32 [15698839.001]
  • (PMID = 16220299.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Membrane Proteins
  •  go-up   go-down


13. Meng ZL, Guo LN, Luo YF, Cao JL, Wan JW, Liu TH: [Role of HPV DNA detection and p16(INK4A) protein expression in diagnosis of endocervical adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Dec;36(12):810-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of HPV DNA detection and p16(INK4A) protein expression in diagnosis of endocervical adenocarcinoma].
  • OBJECTIVES: To evaluate the significance of p16(INK4A) protein expression and positivity for HPV DNA in distinguishing between endocervical and endometrial adenocarcinoma.
  • METHODS: Expression of p16(INK4A) protein in 30 cases of endocervical adenocarcinoma and 10 cases of endometrial adenocarcinoma was assessed by immunohistochemistry.
  • In-situ hybridization for human papillomavirus (HPV) DNA was also performed in 20 cases of endocervical adenocarcinoma and 10 cases of endometrial adenocarcinoma.
  • RESULTS: The positive rate for p16(INK4A) in endocervical adenocarcinoma was 70% (21/30), as compared with 30% (3/10) in endometrial adenocarcinoma.
  • The tumor cells in endocervical adenocarcinoma showed diffuse and strong expression of p16(INK4A) protein with both cytoplasmic and nuclear staining.
  • In contrast, the endometrial adenocarcinoma cells showed patchy and weak expression of p16(INK4A).
  • On the other hand, HPV DNA (type 16 or 18) was detected by in-situ hybridization in 9 (45%) of the 20 cases of endocervical adenocarcinoma and none of the 10 cases of endometrial adenocarcinoma.
  • CONCLUSIONS: The expression of p16(INK4A) protein is significantly higher in endocervical adenocarcinoma than in endometrial adenocarcinoma.
  • This expression pattern can serve as a useful immunohistochemical marker in the differential diagnosis. p16(INK4A) protein immunohistochemistry appears to be more sensitive than HPV DNA testing in distinguishing between endocervical and endometrial adenocarcinoma, especially in biopsy or curettage specimens.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA, Viral / analysis. Gene Expression Regulation, Neoplastic. Human papillomavirus 16 / genetics. Human papillomavirus 18 / genetics. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346352.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  •  go-up   go-down


14. Lehrbach DM, Cecconello I, Ribeiro Jr U, Capelozzi VL, Ab'saber AM, Alves VA: Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions. Arq Gastroenterol; 2009 Oct-Dec;46(4):315-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions.
  • CONTEXT: Esophagogastric junction adenocarcinoma has an aggressive behavior, and TNM (UICC) staging is not always accurate enough to categorize patient's outcome.
  • OBJECTIVES: To evaluated p53, cyclin D1 and Bcl-2 immunoexpressions in esophagogastric junction adenocarcinoma patients, without Barrett's esophagus, and to compared to clinicopathological characteristics and survival rate.
  • RESULTS: Fifty (66.7%) of the tumors were intestinal type and 25 (33.3%) were diffuse.


15. Chandanos E, Lindblad M, Rubio CA, Jia C, Warner M, Gustafsson JA, Lagergren J: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer; 2008 May;44(7):1007-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure in relation to gastric adenocarcinoma development.
  • Epidemiological research has indicated that the anti-oestrogen tamoxifen, used in breast cancer therapy, may increase the risk of gastric adenocarcinoma of the intestinal but not of the diffuse type.
  • Tumour material was reviewed histologically to verify gastric adenocarcinoma diagnosis and classify these cancers into intestinal or diffuse type.
  • Amongst 68 women with verified gastric adenocarcinoma, 30 had been treated with tamoxifen and 38 not.
  • The intestinal type of gastric adenocarcinoma was not more frequent amongst tamoxifen users (27%) than amongst non-users (34%) (p=0.601).
  • There were no material differences between the tamoxifen groups regarding distribution of any of the three ERs of the intestinal adenocarcinoma specimens.
  • Tamoxifen users had a shorter latency between breast cancer and gastric adenocarcinoma (4 versus 13 years) which was similar in the intestinal and diffuse types.
  • This study does not support the hypothesis that tamoxifen increases the isolated risk of the intestinal type, but it indicates that tamoxifen use might accelerate the tumour progression or increase the overall risk of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394879.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


16. Hosseini HA, Ahani A, Galehdari H, Froughmand AM, Hosseini M, Masjedizadeh A, Zali MR: Frequent loss of heterozygosity at 8p22 chromosomal region in diffuse type of gastric cancer. World J Gastroenterol; 2007 Jun 28;13(24):3354-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent loss of heterozygosity at 8p22 chromosomal region in diffuse type of gastric cancer.
  • AIM: To study the loss of heterozygosity (LOH) at 8p21-23 locus in diffuse gastric cancer.
  • METHODS: To evaluate the involvement of this region in gastric cancer, we used eight microsatellite markers covering two Mb of mentioned region, to perform a high-resolution analysis of allele loss in 42 cases of late diffuse gastric adenocarcinoma.

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659675.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / N-acetyltransferase 1; EC 2.3.1.5 / NAT2 protein, human
  • [Other-IDs] NLM/ PMC4172716
  •  go-up   go-down


17. Lee CK, Chang YW, Jung SH, Jang JY, Dong SH, Kim HJ, Kim BH, Chang R: [A case of Sister Mary Joseph's nodule as a presenting sign of gastric cancer]. Korean J Gastroenterol; 2008 Feb;51(2):132-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffuse irregular thickening of peritoneum and diffuse wall thickening of stomach implied the diagnosis of gastric cancer.
  • Esophagogastroduodenoscopy revealed diffuse nodular infiltrative lesion from cardia through body of the stomach, compatible with Bormann type 4 advanced gastric cancer.
  • Later, histopathologic confirmation showed a presence of signet ring cell adenocarcinoma from biopsy specimens.
  • We experienced a case presenting with an umbilical metastasis as the first sign of gastric adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349576.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


18. Oh SY, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim CO, Kim SJ, Jeong JS, Kim HJ: Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer; 2008;8:123
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The positive rates of p53 and HIF-1alpha (diffuse, deep, intravascular pattern) were 38.6% and 15.8%, respectively.
  • VEGF overexpression was more frequently observed in the old age group (> or = 60 years old) and the intestinal type (P = 0.013, P = 0.014, respectively).
  • [MeSH-major] Adenocarcinoma / blood. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Stomach Neoplasms / blood. Tumor Suppressor Protein p53 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213 [17324579.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1207-25 [11181687.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2911-6 [11306467.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3436-44 [11313469.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):281-90 [17603752.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):88-91 [8538748.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1661-8 [11410504.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5215-22 [11431362.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 1;128(1):31-4 [11454426.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6548-54 [11522653.001]
  • [Cites] Cancer Lett. 2002 Feb 25;176(2):215-23 [11804750.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(2):184-91 [12509950.001]
  • [Cites] Cancer Lett. 2003 Mar 31;192(2):215-25 [12668286.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Cancer Sci. 2003 Aug;94(8):735-40 [12901801.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):206-15 [14710231.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4109-17 [15217947.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):200-8 [15245814.001]
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):6264-77 [8065358.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):826-32 [9053510.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2067-72 [9179052.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104-9 [9223322.001]
  • [Cites] Eur Surg Res. 1998;30(2):130-7 [9565747.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5678-80 [9865721.001]
  • [Cites] Histol Histopathol. 1999 Jan;14(1):279-84 [9987672.001]
  • [Cites] J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S407-9 [15838334.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • (PMID = 18452596.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2397429
  •  go-up   go-down


19. Hattori M, Inui K, Yoshino J, Miyoshi H, Okushima K, Nakamura Y, Naito T, Imaeda Y, Horibe Y, Hattori T, Nakazawa S: [Usefulness of contrast-enhanced ultrasonography in the differential diagnosis of polypoid gallbladder lesions]. Nihon Shokakibyo Gakkai Zasshi; 2007 Jun;104(6):790-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the usefulness of contrast-enhanced ultrasonography for differential diagnosis of polypoid gallbladder lesions in 60 patients, consisting of gallbladder carcinoma in 20, adenoma in 2, benign polyp in 29, and adenomyomatosis in 9, comparing contrast enhancement patterns with pathologic findings.
  • Contrast enhancement patterns were classified as linear, scattered, diffuse, or branched.
  • When diffuse type and branched type were considered as indicative of cancer, accuracy was 84.5%, sensitivity 100%, and specificity 76.9%.
  • In gallbladder carcinoma, the TIC rose from no contrast to early-phase contrast sooner than in other diseases.
  • In adenocarcinoma, high-intensity values persisted at 120 sec.
  • With an intensity of 90 or greater at 120 sec taken as indicating cancer, accuracy was 89.7%, sensitivity 89.5%, and specificity 89.7%; Vessels were significantly more numerous in diffuse type cases than in those with other patterns.
  • Vessel diameter was greatest in the diffuse type and the branched type patterns, both differing significantly from the linear type.

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548945.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


20. Carneiro F, Moutinho C, Pera G, Caldas C, Fenger C, Offerhaus J, Save V, Stenling R, Nesi G, Mahlke U, Bläker H, Torrado J, Roukos DH, Sabourin JC, Boeing H, Palli D, Bueno-de-Mesquita HB, Overvad K, Bingham S, Clavel-Chapelon F, Lund E, Trichopoulou A, Manjer J, Riboli E, Gonzalez CA: Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Scand J Gastroenterol; 2007 May;42(5):618-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Cardia, non-cardia and intestinal and diffuse subtypes of gastric cancer may have different trends and etiological factors.
  • Among cases submitted to histopathological validation reported originally as unknown histotype or unknown site, a specific diagnosis was made in 95% and 74% of the cases, respectively.
  • Gastric adenocarcinomas were classified according to site (cardia (29.4%), non-cardia (48.2%) and unknown (22.4%)) and histological type (intestinal (33.4%), diffuse (33.7%) and mixed, unclassified or unknown (32.9%)).
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Paraffin Embedding / methods. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454883.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105630924
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


21. Mansor S, McCluggage WG: Cervical adenocarcinoma resembling breast lobular carcinoma: a hitherto Undescribed Variant of Primary Cervical Adenocarcinoma. Int J Gynecol Pathol; 2010 Nov;29(6):594-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenocarcinoma resembling breast lobular carcinoma: a hitherto Undescribed Variant of Primary Cervical Adenocarcinoma.
  • Most cervical adenocarcinomas are of the so-called usual or endocervical type, and consist entirely or predominantly of glandular formations.
  • We describe 3 cases of an unusual morphologic variant of cervical adenocarcinoma largely composed of bland epithelial cells, with occasional intracytoplasmic lumina, arranged in a variety of architectural patterns, including diffuse, small glandular, insular, trabecular, and Indian file arrangements.
  • The overall appearances closely resembled a breast lobular carcinoma.
  • In all cases, there was a minor superficial component of well-differentiated adenocarcinoma, suggesting that the component that resembled breast lobular carcinoma, arose from the differentiated neoplasm.
  • All cases were diffusely p16-positive, and 2 that underwent human papillomavirus testing contained high-risk oncogenic human papillomavirus, type 16 and 18 in 1 case each.
  • In all cases, there was loss of e-cadherin membranous immunoreactivity in the areas resembling breast lobular carcinoma, a similar pattern of staining to that seen in the latter neoplasm and possibly accounting for the morphologic features.
  • In reporting these cases, we highlight an unusual morphologic variant of cervical adenocarcinoma closely resembling breast lobular carcinoma and which may have an aggressive behavior.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Female. Humans. Immunohistochemistry. Middle Aged


22. Ismail HM, Moneer M, El-Baradie M, Khorshid O, Touny A: Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray. J Egypt Natl Canc Inst; 2007 Jun;19(2):147-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.
  • BACKGROUND: The aim of the study was to verify the frequency of the immunohistochemical overexpression of her-2/neu and p53 in gastric carcinoma and their relation to the other clinico-pathological features and the impact on survival rates.
  • PATIENTS AND METHODS: A total of 93 patients of gastric carcinoma, who had a potential curative surgery in the period from 2001-2007 and with representative paraffin blocks, and sufficient follow-up data were included in this study.
  • None of the examined clinico-pathologic factors had a significant relation to her-2/neu overexpression. p53 was overexpressed in intestinal type, 14/34 (41.2%), more than in diffuse type, 10/59 (16.9%), (p= 0.01).
  • CONCLUSION: Although, this study failed to show any prognostic effect of p53 and her-2/neu on survival rates, we may suggest that p53 overexpression may play a role in the pathogenesis of intestinal gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Adenocarcinoma, Mucinous / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / therapy. Receptor, ErbB-2 / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19034345.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


23. Kim SR, Imoto S, Nakajima T, Ando K, Mita K, Fukuda K, Nishikawa R, Koma Y, Matsuoka T, Kudo M, Hayashi Y: Scirrhous hepatocellular carcinoma displaying atypical findings on imaging studies. World J Gastroenterol; 2009 May 14;15(18):2296-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scirrhous hepatocellular carcinoma displaying atypical findings on imaging studies.
  • We describe a 15-mm scirrhous hepatocellular carcinoma (HCC) in a 60-year-old man with B-type cirrhosis.
  • Contrast-enhanced US revealed heterogeneous, not diffuse, hypervascularity in the early phase and a defect in the Kupffer phase.
  • [MeSH-major] Adenocarcinoma, Scirrhous. Carcinoma, Hepatocellular

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1980 Jul 15;46(2):372-9 [6248194.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Sep;21(9):1470-7 [16911695.001]
  • [Cites] Hum Pathol. 1988 Jul;19(7):784-94 [2456977.001]
  • [Cites] Liver. 1981 Mar;1(1):33-49 [6294435.001]
  • (PMID = 19437576.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2682251
  •  go-up   go-down


24. Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, Nafteux P, Penninckx F, Geboes K, Lerut T, Ectors N: Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg; 2006 Mar;243(3):334-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adenocarcinomas were subtyped according to the Lauren classification (intestinal- and diffuse-type).
  • However, intestinal-type adenocarcinomas showed a significantly higher expression of CA IX as well as VEGF than diffuse-type tumors.
  • CONCLUSION: The difference in expression of CA IX and VEGF between intestinal- and diffuse-type adenocarcinomas may possibly explain the different clinical behavior of these tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / biosynthesis. Biomarkers, Tumor / biosynthesis. Carbonic Anhydrases / biosynthesis. Esophageal Neoplasms / metabolism. Stomach Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Feb;54(2):116-20 [11215279.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):59-65 [11191064.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5262-7 [11431368.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] J Hepatol. 2001 Nov;35(5):643-9 [11690711.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(2):240-57 [11803141.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1284-91 [11948144.001]
  • [Cites] J Pathol. 2002 Jul;197(3):314-21 [12115877.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):473-82 [12560438.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):166-70 [12633560.001]
  • [Cites] Bioorg Med Chem Lett. 2003 Mar 24;13(6):1005-9 [12643899.001]
  • [Cites] J Surg Oncol. 2003 Apr;82(4):234-40 [12672007.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1398-403 [12854129.001]
  • [Cites] Radiother Oncol. 2004 Mar;70(3):225-30 [15064006.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] APMIS. 1988 May;96(5):379-94 [3288247.001]
  • [Cites] EMBO J. 1989 Dec 1;8(12):3801-6 [2684646.001]
  • [Cites] Surg Gynecol Obstet. 1991 Sep;173(3):223-6 [1925884.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):268-74 [8486430.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):598-609 [8080042.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2877-88 [8084592.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • [Cites] Hum Pathol. 1995 May;26(5):504-8 [7750934.001]
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):88-91 [8538748.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):213-4 [8617469.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):398-408 [9024293.001]
  • [Cites] Breast Cancer Res Treat. 1997 Jan;42(2):165-72 [9138605.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):740-4 [9191010.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2827-31 [9230182.001]
  • [Cites] Ann Thorac Surg. 1997 Jul;64(1):185-91; discussion 191-2 [9236358.001]
  • [Cites] J Histochem Cytochem. 1998 Apr;46(4):497-504 [9524195.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):279-85 [9665489.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Surgery. 1999 Feb;125(2):195-201 [10026754.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Mol Med Today. 2000 Jan;6(1):15-9 [10637570.001]
  • [Cites] Br J Cancer. 2000 Jun;82(11):1808-13 [10839295.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1621-30 [10959048.001]
  • [Cites] Histochem Cell Biol. 2000 Sep;114(3):197-204 [11083462.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • (PMID = 16495697.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC1448952
  •  go-up   go-down


25. Kim JY, Park DY, Kim GH, Choi KU, Lee CH, Huh GY, Sol MY, Song GA, Jeon TY, Kim DH, Sim MS: Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma. Histol Histopathol; 2005 04;20(2):543-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma.
  • The purpose of this study was to elucidate Smad4 expression and localization in 65 gastric adenomas, 49 intestinal-type and 39 diffuse type of gastric adenocarcinomas (including 12 cases of fresh frozen tissue) using Real-time RT-PCR and immunohistochemistry.
  • Real-time RT-PCR showed that intestinal type gastric adenocarcinomas have higher Smad4 mRNA expression than diffuse type gastric adenocarcinomas.
  • Immunohistochemical stain for Smad4 revealed that expression of Smad4 was significantly lower in diffuse-type gastric adenocarcinoma than intestinal-type gastric adenocarcinomas.
  • Also, higher Smad4 protein expression in intestinal type gastric adenocarcinomas than overall gastric adenoma was noted.
  • These results suggest that Smad4 might play different roles in human gastric carcinogenesis, especially between intestinal type and diffuse type of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Trans-Activators / genetics. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736060.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta
  •  go-up   go-down


26. Giaginis CT, Vgenopoulou S, Tsourouflis GS, Politi EN, Kouraklis GP, Theocharis SE: Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res; 2009 Jun;15(2):173-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma.
  • FAK expression was assessed immunohistochemically in tumoral samples of 66 gastric adenocarcinoma cases, 30 intestinal and 36 diffuse type, and was statistically analyzed in relation to various clinicopathological characteristics, tumor proliferative capacity and patients' survival.
  • In intestinal type carcinomas, enhanced FAK expression was significantly associated with increased tumor proliferative capacity (P = 0.012).
  • In diffuse type carcinomas, FAK staining intensity was significantly correlated with tumor size (P = 0.026) and disease stage (P = 0.024), presenting also a borderline association with nodal status (P = 0.053).
  • In diffuse type carcinomas, enhanced FAK expression was significantly associated with longer overall survival times (log-rank test, P = 0.014), being also identified as an independent prognostic factor in multivariate analysis (Cox regression, P = 0.016).
  • In contrast, patients with intestinal type tumors and enhanced FAK expression were characterized by shorter overall survival times, without though reaching statistical significance (log-rank test, P = 0.092).
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Intestinal Neoplasms / enzymology. Stomach Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):633-49 [16997150.001]
  • [Cites] Oncology. 2006;71(5-6):417-22 [17687194.001]
  • [Cites] J Biol Chem. 1992 Sep 25;267(27):19031-4 [1382065.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3272-9 [16740747.001]
  • [Cites] Toxicology. 2008 Mar 12;245(1-2):1-10 [18215454.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):571-4 [12943621.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):651-74 [16997151.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30455-62 [9374537.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2812-7 [15102689.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1087-95 [15466376.001]
  • [Cites] IARC Sci Publ. 2004;(157):327-49 [15055305.001]
  • [Cites] J Cell Sci. 1996 Jul;109 ( Pt 7):1787-94 [8832401.001]
  • [Cites] Histol Histopathol. 2008 May;23 (5):629-50 [18283648.001]
  • [Cites] J Cell Sci. 2000 Dec;113 Pt 23:4221-30 [11069767.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R194-203 [15743500.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2752-5 [7796399.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2417-23 [10873094.001]
  • [Cites] Eur J Surg Oncol. 1986 Jun;12(2):135-41 [3709818.001]
  • [Cites] Histochem Cell Biol. 1996 Jan;105(1):17-25 [8824902.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):359-74 [12884911.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2476-83 [16638855.001]
  • [Cites] World J Gastroenterol. 2006 Feb 7;12(5):686-90 [16521179.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):365-71 [9520949.001]
  • [Cites] Cell Growth Differ. 1996 Apr;7(4):413-8 [9052982.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12 ):2724-32 [16998832.001]
  • [Cites] Expert Opin Ther Targets. 2007 Oct;11(10):1315-28 [17907961.001]
  • [Cites] J Cell Biochem. 2006 Sep 1;99(1):35-52 [16823799.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):613-8 [12174366.001]
  • [Cites] Nature. 1995 Oct 12;377(6549):539-44 [7566154.001]
  • [Cites] Proteomics. 2004 Oct;4(10):3276-87 [15378696.001]
  • [Cites] J Cell Physiol. 1998 Dec;177(4):618-27 [10092214.001]
  • [Cites] Dig Dis Sci. 2008 Jun;53(6):1728-34 [17932753.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2513-24 [11971186.001]
  • [Cites] Lung Cancer. 1997 May;17(1):69-84 [9194028.001]
  • [Cites] World J Surg. 2006 Feb;30(2):219-26 [16425085.001]
  • [Cites] J Cell Biol. 1992 Nov;119(4):905-12 [1385445.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Oct;5(5):415-20 [15544489.001]
  • [Cites] Clin Transl Oncol. 2007 Apr;9(4):208-15 [17462972.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30597-604 [10899173.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):104-11 [15246215.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):140-5 [12838315.001]
  • [Cites] Lung Cancer. 2006 Sep;53(3):263-71 [16842883.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1289-94 [15861214.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • (PMID = 18987997.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases
  •  go-up   go-down


27. Zielonka TM: [Bronchioloalveolar carcinoma]. Pol Merkur Lekarski; 2005 Feb;18(104):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bronchioloalveolar carcinoma].
  • Bronchioloalveolar carcinoma (BALC) is a sub-type of adenocarcinoma, accounting for 3-5% of all lung cancer cases.
  • Their carcinomas were classified into three clinicopathologic types: nodular or tumoral, pneumonic, and diffuse types.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877136.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 44
  •  go-up   go-down


28. Sicinschi LA, Lopez-Carrillo L, Camargo MC, Correa P, Sierra RA, Henry RR, Chen J, Zabaleta J, Piazuelo MB, Schneider BG: Gastric cancer risk in a Mexican population: role of Helicobacter pylori CagA positive infection and polymorphisms in interleukin-1 and -10 genes. Int J Cancer; 2006 Feb 1;118(3):649-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA was extracted from sera of 183 gastric adenocarcinoma patients and 377 controls.
  • A significant interaction was found between IL1B-31 and CagA status for the risk of intestinal-type gastric cancer (p = 0.023).
  • Among CagA positive subjects, those with IL1B-31CC genotype had an increased risk of intestinal-type gastric cancer (OR 3.19, 95%CI = 1.05-9.68), compared to carriers of IL1B-31TT genotype.
  • The IL10-592CC genotype was associated with more than doubling of the risk of the intestinal-type gastric cancer (OR, 2.20, 95%CI = 1.04-4.65).
  • A nonsignificantly increased risk for intestinal-type gastric cancer was found in IL1RN*2 carriers (OR 1.49, 95%CI = 0.89-2.50).
  • None of these polymorphisms was significantly related to the risk of diffuse-type gastric cancer.
  • Individuals carrying 2 or more of the risk-associated alleles (IL1B-31C, IL1RN *2 and IL10-592C) were at increased risk for intestinal-type gastric cancer, compared to those with 0 or 1 risk-associated allele.
  • Our results support the identification of the IL1B-31 promoter polymorphism as a useful marker for risk of intestinal type gastric cancer in persons with CagA positive H. pylori infections.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Bacterial / immunology. Bacterial Proteins / immunology. Helicobacter Infections / genetics. Interleukin-1 / genetics. Interleukin-10 / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16114018.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 28842
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Interleukin-1; 0 / Receptors, Interleukin-1; 0 / cagA protein, Helicobacter pylori; 130068-27-8 / Interleukin-10
  •  go-up   go-down


29. Castañeda-Argáiz R, González-Contreras QH, Medina-Franco H, Rodríguez-Zentner HA, Tapia-Cid de León H, Vergara-Fernández O: [Hereditary non-polyposis colorectal cancer associated with hereditary gastric cancer. A case report.]. Rev Gastroenterol Mex; 2009;74(3):256-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The information regarding the association of gastric cancer and type 2 Lynch syndrome is limited.
  • The hereditary diffuse gastric cancer syndrome is caused by a germ-line mutation in the E-cadherin (CDH1) gene; only about 50 families with this syndrome have been reported.
  • [MeSH-major] Adenocarcinoma / complications. Colorectal Neoplasms, Hereditary Nonpolyposis / complications. Stomach Neoplasms / complications


30. Singh R, Basturk O, Klimstra DS, Zamboni G, Chetty R, Hussain S, La Rosa S, Yilmaz A, Capelli P, Capella C, Cheng JD, Adsay NV: Lipid-rich variant of pancreatic endocrine neoplasms. Am J Surg Pathol; 2006 Feb;30(2):194-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The growth pattern was relatively diffuse, with vague compartmentalization of the cells by a delicate vasculature; prominent nesting was noted in only 4 cases.
  • Pathology reports indicated substantial diagnostic challenge in these cases; on biopsies, 1 case was originally diagnosed as adrenal cortical carcinoma, another as renal cell carcinoma, a third as solid-pseudopapillary tumor, and a fourth had a fine needle aspiration cytologic diagnosis of adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Adrenocortical Carcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Middle Aged. Multiple Endocrine Neoplasia Type 1 / pathology. von Hippel-Lindau Disease / complications

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434893.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lipids
  •  go-up   go-down


31. Kuroda T, Ito M, Wada Y, Kitadai Y, Tanaka S, Yoshida K, Yoshihara M, Haruma K, Merdh S, Chayama K: Presence of poorly differentiated component correlated with submucosal invasion in the early diffuse-type gastric cancer. Hepatogastroenterology; 2008 Nov-Dec;55(88):2264-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of poorly differentiated component correlated with submucosal invasion in the early diffuse-type gastric cancer.
  • BACKGROUND/AIMS: Diffuse-type gastric carcinoma is associated with a poor prognosis.
  • However, the clinical behavior of diffuse-type gastric cancer is not fully understood.
  • The aim of this study is to distinguish the behaviors of early diffuse-type gastric carcinomas by sub classifying tumors according to their histologic features.
  • METHODOLOGY: A total of 114 cases of diffuse-type early gastric cancer were studied retrospectively.
  • We analyzed and compared the resected cancer specimens according to the histologic components: as poorly differentiated adenocarcinoma component-present (poor+) versus poorly differentiated adenocarcinoma component-absent (poor-).
  • CONCLUSIONS: The biologic behavior of poor+ gastric carcinoma is worse than that of poor- carcinoma.
  • There is a close relation between H. pylori infection and carcinogenesis of poorly differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260519.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Gastrins
  •  go-up   go-down


32. Barresi V, Vitarelli E, Grosso M, Tuccari G, Barresi G: Relationship between immunoexpression of mucin peptide cores MUC1 and MUC2 and Lauren's histologic subtypes of gastric carcinomas. Eur J Histochem; 2006 Oct-Dec;50(4):301-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laurèn's system subdivides gastric cancers into an intestinal type and a diffuse type.
  • This histological classification mirrors histogenetic hypotheses according to which the intestinal-type cancer derives from intestinal metaplasia and dysplasia, while the diffuse-type originates directly from gastric mucosa, with or without a preceding non-metaplastic dysplasia.
  • 40 gastric adenocarcinomas, subdivided, according to Laurèn's classification, into 27 intestinal-type, 10 diffuse-type and 3 unclassified cases, were examined for MUC1 and MUC2 immunohistochemical expression.
  • Intestinal-type carcinomas displayed a MUC1-positive staining in 23/27 cases and a MUC2-positive immunoreaction in 10/27 cases.
  • Diffuse-type carcinomas expressed MUC1 in 3/10 and MUC2 in 8/10 cases, respectively.
  • The gastric phenotype was significantly higherin intestinal-type adenocarcinomas, whereas cases showing an intestinal phenotype were significantly more frequent in diffuse-type adenocarcinomas.
  • In particular, the term intestinal-type tumour as referred to gland-forming gastric cancer does not seem to reflect an immunohistochemical phenotype.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Mucins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213039.001).
  • [ISSN] 1121-760X
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


33. Lima EM, Leal MF, Burbano RR, Khayat AS, Assumpção PP, Bello MJ, Rey JA, Smith MA, Casartelli C: Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res; 2008 Jun;41(6):539-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the DNA methylation status of ANAPC1, CDKN2A and TP53 by methylation-specific PCR in 20 diffuse- and 26 intestinal-type gastric cancer samples and 20 normal gastric mucosa in individuals from Northern Brazil.
  • CDKN2A methylation was not detected in any normal gastric mucosa; however, the CDKN2A promoter was methylated in 30.4% of gastric cancer samples, with 35% methylation in diffuse-type and 26.9% in intestinal-type cancers.
  • CDKN2A methylation was associated with the carcinogenesis process for ~30% diffuse-type and intestinal-type compared to non-neoplastic samples.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622497.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / ANAPC1 protein, human; 0 / Apc1 Subunit, Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


34. Zhao L, Shen ZX, Luo HS, Shen L: Possible involvement of leptin and leptin receptor in developing gastric adenocarcinoma. World J Gastroenterol; 2005 Dec 28;11(48):7666-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible involvement of leptin and leptin receptor in developing gastric adenocarcinoma.
  • AIM: To investigate the expression of leptin and leptin receptor (ob-R) in intestinal-type gastric cancer and precancerous lesions, and to explore the possible mechanism and role of the leptin system in developing intestinal-type gastric adenocarcinoma.
  • METHODS: Immunohistochemistry was performed to examine the expression of leptin and leptin receptor in archival samples of gastric adenocarcinoma and preneoplastic lesions, including intestinal metaplasia and mild to severe gastric epithelial dysplasia.
  • RESULTS: Dual expression of leptin and leptin receptor were detected in 80% (16/20) intestinal metaplasia, 86.3% (25/30) mild gastric epithelial dysplasia, 86.7% (26/30) moderate gastric epithelial dysplasia, 93.3% (28/30) severe gastric epithelial dysplasia, 91.3% (55/60) intestinal-type gastric adenocarcinoma and 30.0% (9/30) diffuse-type gastric carcinoma.
  • The percentage of dual expression of leptin and leptin receptor in intestinal-type gastric adenocarcinoma was significantly higher than that in diffuse-type gastric adenocarcinoma (c2 = 37.022, P<0.01).
  • CONCLUSION: Our results indicate the presence of an autocrine loop of leptin system in the development of intestinal-type gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Leptin / physiology. Receptors, Cell Surface / physiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437696.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Other-IDs] NLM/ PMC4727216
  •  go-up   go-down


35. Barresi V, Giuffre' G, Vitarelli E, Todaro P, Tuccari G: Caveolin-1 immuno-expression in human gastric cancer: histopathogenetic hypotheses. Virchows Arch; 2008 Dec;453(6):571-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cav-1 immuno-expression was found in most GC (94%) with a significantly higher amount in the Lauren intestinal type in comparison to the diffuse-type carcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Signet Ring Cell / metabolism. Caveolin 1 / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Mar 15;103(6):1186-94 [15712208.001]
  • [Cites] J Biol Chem. 1997 Nov 14;272(46):29337-46 [9361015.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):929-33 [11920460.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):759-64 [8392033.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8519-26 [17875691.001]
  • [Cites] Acta Neuropathol. 2006 Nov;112(5):617-26 [16850311.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 May;16(3):267-73 [18301242.001]
  • [Cites] Mol Cell. 1999 Mar;3(3):263-74 [10198629.001]
  • [Cites] Science. 1992 Jan 24;255(5043):410-1 [1310359.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):833-9 [11238032.001]
  • [Cites] Neuropathology. 2008 Oct;28(5):472-8 [18282163.001]
  • [Cites] Cancer Lett. 2004 Oct 8;214(1):121-8 [15331180.001]
  • [Cites] Mol Endocrinol. 2000 Nov;14(11):1750-75 [11075810.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2437-42 [9951940.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] J Histochem Cytochem. 1974 Dec;22(12):1135-40 [4140870.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):511-22 [18242217.001]
  • [Cites] J Biol Chem. 2001 Oct 12;276(41):38121-38 [11457855.001]
  • [Cites] Oncol Rep. 2007 Sep;18(3):601-9 [17671707.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):719-24 [11345836.001]
  • [Cites] BJU Int. 2004 Feb;93(3):291-6 [14764125.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10909-13 [8248193.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1635-43 [11696424.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):23368-77 [10816572.001]
  • (PMID = 18936967.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1
  •  go-up   go-down


36. Lomo L, Nucci MR, Lee KR, Lin MC, Hirsch MS, Crum CP, Mutter GL: Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol; 2008 Aug;21(8):937-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic and immunohistochemical decision-making in endometrial adenocarcinoma.
  • Diffuse p53 immunostaining distinguishes 85% of serous (Type II) from endometrioid (Type I) carcinomas and is an independent marker for poor prognosis.
  • Because p53 is an important marker for endometrial adenocarcinoma outcome, and cannot be predicted in advance in indeterminate cases, p53 immunostaining should be employed in cases with observer disagreement in a binary system.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500258.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


37. Osaki M, Inoue T, Yamaguchi S, Inaba A, Tokuyasu N, Jeang KT, Oshimura M, Ito H: MAD1 (mitotic arrest deficiency 1) is a candidate for a tumor suppressor gene in human stomach. Virchows Arch; 2007 Oct;451(4):771-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously confirmed that the level of MAD1 protein was decreased in gastric carcinoma compared with non-tumoral mucosa by conducting proteome-based analyses (Nishigaki R, Osaki M, Hiratsuka M, Toda T, Murakami K, Jeang KT, Ito H, Inoue T, Oshimura M, Proteomics 5:3205-3213, 29).
  • MAD1 was detected in the supranuclear portion of normal epithelial, intestinal metaplasia, and adenoma cells, but its expression was not restricted to any specific area in carcinoma cells.
  • Moreover, the expression of MAD1 was significantly lower in advanced carcinomas than early carcinomas and in intestinal than diffuse type, respectively (P < 0.05).
  • Exogenous expression of wild-type MAD1, but not the mutant MAD1, inhibited cell proliferation and resulted in G2/M accumulation in MKN-1, a gastric carcinoma cell line.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Cycle Proteins / genetics. Genes, Tumor Suppressor. Nuclear Proteins / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 2004 Jun 8;14(11):942-52 [15182667.001]
  • [Cites] EMBO J. 2001 Nov 15;20(22):6371-82 [11707408.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):31005-13 [12042300.001]
  • [Cites] Cancer Genet Cytogenet. 2005 May;159(1):10-7 [15860351.001]
  • [Cites] Pathol Res Pract. 2001;197(4):223-9 [11358006.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):945-57 [16909107.001]
  • [Cites] Anal Quant Cytol Histol. 1999 Apr;21(2):161-5 [10560486.001]
  • [Cites] Oncogene. 2001 May 31;20(25):3301-5 [11423979.001]
  • [Cites] J Cell Biol. 1995 Jun;129(5):1195-204 [7775567.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1090-5 [10070967.001]
  • [Cites] Int J Cancer. 1999 Oct 29;83(3):309-13 [10495421.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1793-6 [11813626.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):815-25 [12415252.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):83-90 [11163156.001]
  • [Cites] Mol Cell Biol. 1994 Dec;14(12):8282-91 [7969164.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):329-33 [15188456.001]
  • [Cites] Cell. 1991 Aug 9;66(3):507-17 [1651171.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):160-6 [17210695.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] Jpn J Cancer Res. 2002 Aug;93(8):857-60 [12716461.001]
  • [Cites] Hum Pathol. 2004 May;35(5):587-93 [15138934.001]
  • [Cites] Oncogene. 2005 Jun 16;24(26):4301-10 [15782113.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Proteomics. 2005 Aug;5(12):3205-13 [16003825.001]
  • [Cites] Mol Biol Cell. 1999 Aug;10(8):2607-18 [10436016.001]
  • [Cites] Cancer Lett. 2005 Dec 8;230(1):6-19 [16253756.001]
  • [Cites] World J Gastroenterol. 2006 May 21;12(19):2979-90 [16718776.001]
  • [Cites] Apoptosis. 1998 Dec;3(6):431-7 [14646476.001]
  • [Cites] J Korean Med Sci. 2000 Apr;15(2):159-66 [10803691.001]
  • [Cites] Trends Cell Biol. 2005 Nov;15(11):589-98 [16214339.001]
  • [Cites] Science. 2002 Sep 27;297(5590):2267-70 [12351790.001]
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):199-203 [11461076.001]
  • [Cites] Histol Histopathol. 2003 Apr;18(2):665-77 [12647816.001]
  • [Cites] Mol Cell. 2002 May;9(5):931-43 [12049731.001]
  • [Cites] J Cell Biol. 2003 Dec 22;163(6):1231-42 [14691134.001]
  • [Cites] Cell. 2002 Apr 5;109(1):113-24 [11955451.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2847-51 [11306456.001]
  • [Cites] Mol Cell. 2002 Jan;9(1):59-71 [11804586.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • (PMID = 17674037.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / MAD1L1 protein, human; 0 / Nuclear Proteins
  •  go-up   go-down


38. Calculli L, Pezzilli R, Brindisi C, Morabito R, Casadei R, Zompatori M: Pancreatic and extrapancreatic lesions in patients with intraductal papillary mucinous neoplasms of the pancreas: a single-centre experience. Radiol Med; 2010 Apr;115(3):442-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients (4.2%) had type I, 103 (72.5%) type II and 33 (23.2%) type III IPMN.
  • RESULTS: Pancreatic IPMN was localised in the head in 43 patients (30.3%), in the body in 13 (9.2%), in the tail in ten (7.0%), in the head-body in 17 (12.0%), in the body-tail in 15 (10.6%) diffuse throughout the gland in 44 (31.0%).
  • In evaluating the distribution of pancreatic or extrapancreatic diseases according to IPMN type, we found that this was not significantly different among types I, II and III (p=0.776).
  • CONCLUSIONS: The majority of pancreatic and extrapancreatic cancers occur before the diagnosis of IPMNs is made and is not related to the type of IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Diagnostic Imaging. Neoplasms, Multiple Primary / pathology. Neoplasms, Second Primary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 2007 May-Jun;32(3):374-80 [16967247.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] J Magn Reson Imaging. 2005 Mar;21(3):237-44 [15723374.001]
  • [Cites] Radiology. 2006 Feb;238(2):560-9 [16436817.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Abdom Imaging. 2006 May-Jun;31(3):320-5 [16333711.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):441-7 [10658722.001]
  • [Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1579-81 [17708304.001]
  • [Cites] Int J Cancer. 2009 Aug 1;125(3):666-73 [19382179.001]
  • [Cites] Surgery. 2006 Jun;139(6):749-54 [16782429.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2008 Apr;7(2):192-5 [18397857.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):803-13; discussion 813-4 [17481488.001]
  • [Cites] J Gastroenterol. 2008;43(3):181-5 [18373159.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):460-8 [16616351.001]
  • [Cites] Radiology. 1986 Dec;161(3):697-700 [3786719.001]
  • [Cites] Radiographics. 2005 Nov-Dec;25(6):1451-68; discussion 1468-70 [16284127.001]
  • [Cites] Radiol Med. 2008 Apr;113(3):414-28 [18493777.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):124-32 [15827792.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):157-62 [14530644.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):323-37; discussion 337-40 [11259696.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):304-7 [17693271.001]
  • [Cites] Clin Radiol. 2006 Sep;61(9):776-83 [16905386.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2878-82 [18853975.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • (PMID = 20082228.001).
  • [ISSN] 1826-6983
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


39. Hamilton JP, Meltzer SJ: A review of the genomics of gastric cancer. Clin Gastroenterol Hepatol; 2006 Apr;4(4):416-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are 2 distinct histologic types of gastric adenocarcinoma, and these types differ in their epidemiology, pathogenesis, genetic profile, and clinical outcome.
  • The pathogenesis of intestinal-type gastric cancer follows a multistep progression that usually is initiated by H pylori infection.
  • A wide range of genetic and epigenetic abnormalities including point mutation, loss of heterozygosity, microsatellite instability, and hypermethylation are described in intestinal-type gastric cancer and its precursor lesions.
  • In contrast to the intestinal-type, diffuse-type gastric cancer is defined by a lack of precursor lesions; mutation or epigenetic silencing of the E-cadherin gene appears to be the key carcinogenic event.
  • [MeSH-major] Adenocarcinoma / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616344.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 176
  •  go-up   go-down


40. Pardo J, Torres W, Martinez-Peñuela A, Panizo A, de Alava E, García JL: Pseudomesotheliomatous carcinoma of the lung with a distinct morphology, immunohistochemistry, and comparative genomic hybridization profile. Ann Diagn Pathol; 2007 Aug;11(4):241-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomesotheliomatous carcinoma of the lung with a distinct morphology, immunohistochemistry, and comparative genomic hybridization profile.
  • We report 4 cases of pseudomesotheliomatous carcinoma of the lung, which has clinical and microscopic features similar to malignant mesothelioma, but with ultrastructural, immunohistochemical, and molecular characteristics suggestive of a histogenesis from type II pneumocytes.
  • Neoplasm grows as a diffuse or solid pattern of large polygonal cells with sharply defined borders.
  • Our aim is to complement the current understanding of this pseudomesotheliomatous "pneumocytic" carcinoma and alert pathologists to this rare entity to avoid misdiagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Aneuploidy. Lung Neoplasms / pathology. Mesothelioma / pathology. Nucleic Acid Hybridization / methods


41. Saad RS, Ismiil N, Dubé V, Nofech-Mozes S, Khalifa MA: CDX-2 expression is a common event in primary intestinal-type endocervical adenocarcinoma. Am J Clin Pathol; 2009 Oct;132(4):531-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX-2 expression is a common event in primary intestinal-type endocervical adenocarcinoma.
  • We studied the expression of cytokeratin (CK) 7, CK20, CDX-2, and p16 in 119 cervical adenocarcinomas (65 usual type [50 invasive; 15 in situ], 37 intestinal type [21 invasive; 16 in situ], 10 endometrioid, 5 adenosquamous, and 2 signet-ring carcinomas) in comparison with 55 cases of rectal adenocarcinomas.
  • CK20 immunostaining was diffuse in the majority of rectal tumors but focal in most cervical tumors.
  • CDX-2 was expressed in all cases of rectal adenocarcinoma and in 46 cervical adenocarcinomas (38.7%): usual type, 10 (15%); intestinal type, 31 (84%); endometrioid type, 5 (50%); adenosquamous and signet-ring types, 0 (0%).
  • [MeSH-major] Adenocarcinoma / physiopathology. Homeodomain Proteins / biosynthesis. Trans-Activators / biosynthesis. Uterine Cervical Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762530.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


42. Shin SH, Jung H, Choi SH, An JY, Choi MG, Noh JH, Sohn TS, Bae JM, Kim S: Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. Ann Surg Oncol; 2009 May;16(5):1304-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Three hundred and nineteen patients with proximal gastric adenocarcinoma who underwent curative total gastrectomy with simultaneous splenectomy and D2 lymph node dissection at the Samsung Medical Center between 1995 and 2004 were analyzed retrospectively.
  • The splenic hilar metastasis group was shown to have a higher proportion of females (48.8%), Borrmann type IV (34.1%), tumor size >5 cm (82.9%), poorly differentiated adenocarcinoma (51.2%), signet ring cell carcinoma (31.7%), Lauren diffuse-type (80.5%), endolymphatic invasion (65.5%), and nerve invasion (46.4%; p < 0.05).
  • [MeSH-major] Adenocarcinoma / pathology. Lymph Nodes / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241107.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Kanechorn Na Ayuthaya R, Patthamapasphong N, Sura T, Niumpradit N, Trachoo O: Ehlers-Danlos syndrome type IV with gastric adenocarcinoma. J Med Assoc Thai; 2008;91 Suppl 1:S166-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ehlers-Danlos syndrome type IV with gastric adenocarcinoma.
  • The vascular type (type IV) is characterized by thin, translucent skin, easy bruising, characteristic facial appearance, and arterial, intestinal, and/or uterine fragility.
  • A first case of EDS type IV with adeno-carcinoma of the stomach in Thailand was reported and literature was reviewed.
  • Abdominal aortic aneurysm were detected with upper gastrointestinal hemorrhage, esophagogastroduodenoscopy showed diffuse gastric body swelling and erythema resulting in chronic gastritis.
  • Gastric biopsy was indicative of adenocarcinoma of the stomach and gastrectomy was done.
  • A vascular EDS type IV was diagnosed.
  • [MeSH-major] Adenocarcinoma / complications. Ehlers-Danlos Syndrome / etiology. Stomach Neoplasms / complications
  • [MeSH-minor] Collagen Type III / genetics. Fatal Outcome. Gastrectomy. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Ehlers-Danlos syndrome.
  • MedlinePlus Health Information. consumer health - Ehlers-Danlos Syndrome.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672610.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / COL3A1 protein, human; 0 / Collagen Type III
  •  go-up   go-down


44. Tot T, Gere M: Radiological-pathological correlation in diagnosing breast carcinoma: the role of pathology in the multimodality era. Pathol Oncol Res; 2008 Jun;14(2):173-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological-pathological correlation in diagnosing breast carcinoma: the role of pathology in the multimodality era.
  • Breast carcinoma is a lobar disease, as the simultaneously or asynchronously appearing often multiple tumor foci originate from a single sick breast lobe.
  • All these variations are properly characterized by the following parameters: the extent of the disease (the volume of the tissue containing all the actually present malignant structures within the breast), the distribution of the lesions within this tissue (unifocal, multifocal or diffuse, separately for in situ and invasive component), the size of the tumor (corresponding to the largest diameter of the largest invasive focus) and the exact localization of the lesion(s).
  • Discordant results may still appear as a consequence of failure in radiological-pathological correlation or related to certain tumor subtypes as invasive lobular carcinoma of diffuse type, low grade in situ lesions or micropapillary ductal in situ carcinoma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2000 Oct;437(4):338-44 [11097355.001]
  • [Cites] Virchows Arch. 1994;425(3):243-8 [7812509.001]
  • [Cites] J Cancer Res Clin Oncol. 1987;113(5):481-7 [3040768.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jun;97(3):285-91 [16791485.001]
  • [Cites] Med Sci Monit. 2006 Aug;12(8):RA170-5 [16865079.001]
  • [Cites] AJR Am J Roentgenol. 2001 Feb;176(2):399-406 [11159081.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2551-60 [17932896.001]
  • [Cites] Radiology. 2004 Dec;233(3):830-49 [15486214.001]
  • [Cites] Acta Radiol. 1999 Jul;40(4):369-75 [10394863.001]
  • [Cites] Lancet. 1990 Mar 3;335(8688):519-22 [1968538.001]
  • [Cites] Int J Surg Pathol. 2007 Oct;15(4):369-75 [17913943.001]
  • [Cites] Br J Radiol. 2003 Jan;76(901):3-12 [12595319.001]
  • [Cites] Eur Radiol. 2004 Jul;14(7):1209-16 [15024602.001]
  • [Cites] Breast. 2007 Aug;16(4):425-8 [17374484.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):718-24 [12937980.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):647-59 [11241230.001]
  • [Cites] Hum Pathol. 2007 Dec;38(12 ):1754-9 [17868777.001]
  • [Cites] Eur Radiol. 2004 May;14(5):809-16 [14615904.001]
  • [Cites] Radiology. 2002 Aug;224(2):569-76 [12147858.001]
  • [Cites] Eur Radiol. 2006 Mar;16(3):692-701 [16328447.001]
  • [Cites] J Clin Ultrasound. 2004 Sep;32(7):323-32 [15293298.001]
  • [Cites] Virchows Arch. 2005 Jul;447(1):1-8 [15926070.001]
  • [Cites] Hum Pathol. 2007 Dec;38(12):1736-43 [17714759.001]
  • [Cites] Ann Pathol. 2000 May;20(3):275-9 [10891733.001]
  • [Cites] Eur Radiol. 2003 Nov;13(11):2425-35 [12898176.001]
  • [Cites] Eur J Radiol. 2003 Dec;48(3):285-92 [14652148.001]
  • (PMID = 18521722.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 32
  •  go-up   go-down


45. Yu J, Bhargava R, Dabbs DJ: Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studies. Diagn Pathol; 2010;5:36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studies.
  • We present a unique case of classical type ILC with abundant extracellular mucin and strong ERBB2 (HER2/neu) expression confirmed by immunohistochemistry and fluorescent in situ hybridization.
  • Dual E-cadherin/p120 immunohistochemical stain demonstrated complete loss of membranous E-cadherin and the presence of diffuse cytoplasmic p120 staining, confirming the lobular phenotype.
  • The findings suggest that the presence of extracellular mucin does not exclude a diagnosis of lobular carcinoma, and the morphologic and molecular characteristics of lobular and ductal carcinomas are more complex than previously appreciated.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Carcinoma, Lobular / chemistry. Mucin-1 / analysis. Receptor, ErbB-2 / analysis


46. Chandanos E, Rubio CA, Lindblad M, Jia C, Tsolakis AV, Warner M, Gustafsson JA, Lagergren J: Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma. Gastric Cancer; 2008;11(3):168-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma.
  • BACKGROUND: Estrogen might protect women against gastric adenocarcinoma of the intestinal histological type.
  • METHODS: A population-based cohort of patients with gastric adenocarcinoma diagnosed in 1958-2004 in the county of Stockholm was identified through the Swedish Cancer Register.
  • Tumor specimens were reviewed, and 289 cases were classified into intestinal (n=101) or diffuse type (n=188).
  • RESULTS: Compared to "exposed women", the intestinal type of gastric adenocarcinoma was more than four times more common among "unexposed men" (odds ratio [OR], 4.7; 95% confidence interval [CI], 2.2-10.3) and nine times more common among "unexposed women" (OR, 9.1; 95% CI, 4.3-19.6).
  • CONCLUSION: Gastric adenocarcinoma of the intestinal type is less common in women with high endogenous estrogen exposure, indicating a preventive effect of estrogen.
  • [MeSH-major] Adenocarcinoma / pathology. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):869-74 [11075877.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 May;19(5):687-9 [6683640.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5932-7 [10606238.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):136-41 [16404367.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):408-12 [12704678.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5331-5 [11454669.001]
  • [Cites] Ann Epidemiol. 2006 Dec;16(12):908-16 [16843679.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1251-8 [12763213.001]
  • [Cites] Cancer. 1977 Jun;39(6):2475-85 [872047.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):305-8 [2070329.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2537-41 [11289127.001]
  • [Cites] Am J Med. 1999 May;106(5):574-82 [10335731.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30 [8650195.001]
  • [Cites] Cancer. 1993 May 15;71(10):2926-33 [8490820.001]
  • [Cites] Cancer Res. 1984 Oct;44(10):4670-4 [6467220.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):885-8 [7657118.001]
  • [Cites] Int J Cancer. 1999 Oct 8;83(2):223-9 [10471531.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2203-7 [15598781.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):991-1004 [14999111.001]
  • [Cites] Mod Pathol. 1994 Jan;7(1):55-8 [8159653.001]
  • [Cites] Cancer. 1991 May 1;67(9):2401-6 [2013043.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):905-31 [17615392.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):761-4 [7989115.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):812-5 [8119771.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):833-8 [11857364.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3955-62 [17440111.001]
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):195-201 [17046193.001]
  • [Cites] Cancer. 1974 Apr;33(4):1190-5 [4362106.001]
  • [Cites] JAMA. 2002 Jul 17;288(3):321-33 [12117397.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1789-98 [17521398.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5769-76 [15355905.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2421-8 [15073120.001]
  • [Cites] Science. 1986 Mar 7;231(4742):1150-4 [3753802.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):786-90 [10328109.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):118-22 [16755290.001]
  • [Cites] Gastroenterol Clin North Am. 2000 Sep;29(3):579-92, v-vi [11030074.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jun;128(6):319-24 [12073050.001]
  • [Cites] Int J Epidemiol. 2007 Feb;36(1):66-76 [17227779.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 9;247(1):75-8 [9636657.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):53-9 [12708725.001]
  • [Cites] Gut. 2007 Dec;56(12):1671-7 [17627962.001]
  • [Cites] Eur J Cancer Prev. 2007 Aug;16(4):312-27 [17554204.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2959-64 [16477031.001]
  • [Cites] Nucleic Acids Res. 1998 Aug 1;26(15):3505-12 [9671811.001]
  • (PMID = 18825311.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Protein Isoforms
  •  go-up   go-down


47. Shin SH, Bae JM, Jung H, Choi MG, Lee JH, Noh JH, Sohn TS, Kim S: Clinical significance of the discrepancy between preoperative and postoperative diagnoses in gastric cancer patients. J Surg Oncol; 2010 Apr 1;101(5):384-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: A total of 2,910 patients with gastric adenocarcinoma underwent curative surgery at the Samsung Medical Center between 2001 and 2003.
  • The EGC-AGC group showed higher proportions of the followings than the EGC-EGC group: upper-third and middle-third tumor localizations, a tumor size from 2 to 5 cm, undifferentiated adenocarcinoma, Lauren's diffuse type, endolymphatic invasion, vascular invasion, and perineural invasion.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20127892.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Oka T, Yamamoto H, Sasaki S, Ii M, Hizaki K, Taniguchi H, Adachi Y, Imai K, Shinomura Y: Overexpression of beta3/gamma2 chains of laminin-5 and MMP7 in biliary cancer. World J Gastroenterol; 2009 Aug 21;15(31):3865-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: LNgamma2 expression was predominantly observed in carcinoma cells at the invasive front.
  • LNgamma2 expression was seen in 57% of patients with biliary tract cancer, and was associated with depth of invasion, histologic type, and advanced stage.
  • The expression pattern of LNbeta3 was classified into two types: invasive front dominant type (38%) and diffuse type (28%).
  • The invasive front dominant type was associated with histologic type and advanced stage.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Animals. Cell Line, Tumor. Female. Humans. Male. Middle Aged. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1991 May 17;65(4):599-610 [2032285.001]
  • [Cites] Pathol Int. 2004 Sep;54(9):688-92 [15363037.001]
  • [Cites] Am J Pathol. 1994 Oct;145(4):782-91 [7943170.001]
  • [Cites] FEBS Lett. 1995 Jul 24;368(3):556-8 [7635220.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):4132-9 [7664291.001]
  • [Cites] Am J Pathol. 1995 Oct;147(4):1123-32 [7573357.001]
  • [Cites] J Biochem. 1996 Dec;120(6):1196-202 [9010770.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1290-6 [9098015.001]
  • [Cites] Science. 1997 Jul 11;277(5323):225-8 [9211848.001]
  • [Cites] J Pathol. 1998 May;185(1):44-52 [9713359.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3313-6 [10416584.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1033-8 [10514384.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2353-60 [15333466.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1375-83 [16285938.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7946-52 [16007117.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jan;231(1):20-7 [16380641.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11228-37 [17145868.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jan;61(1):44-51 [17164111.001]
  • [Cites] J Pathol. 2007 Apr;211(5):516-23 [17318812.001]
  • [Cites] J Pathol. 2007 May;212(1):102-11 [17370299.001]
  • [Cites] Cancer Lett. 2007 Aug 28;254(1):42-53 [17374440.001]
  • [Cites] Curr Probl Surg. 2007 Jul;44(7):396-482 [17693325.001]
  • [Cites] J Pathol. 2007 Oct;213(2):131-9 [17724792.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5596-601 [10554040.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):615-24 [10662785.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1129-35 [11238061.001]
  • [Cites] Mol Carcinog. 2001 Feb;30(2):119-29 [11241759.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):896-900 [11309339.001]
  • [Cites] Int J Cancer. 2001 Sep 20;95(5):290-4 [11494227.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8089-93 [11719433.001]
  • [Cites] Semin Cancer Biol. 2002 Jun;12(3):197-207 [12083850.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3684-91 [14506159.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):490-9 [14726470.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):627-35 [8348847.001]
  • (PMID = 19701966.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / LAMC2 protein, human; 0 / Laminin; 0 / RNA, Small Interfering; 0 / kalinin; 170834-93-2 / laminin alpha 3; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  • [Other-IDs] NLM/ PMC2731248
  •  go-up   go-down


49. Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S, Assumpção PP, Faria MH, Rabenhorst SH, Ferreira MV, de Arruda Cardoso Smith M, Burbano RR: Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma. World J Gastroenterol; 2006 Oct 14;12(38):6207-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma.
  • RESULTS: All the cases showed chromosome 8 aneuploidy and C-MYC amplification, in both the diffuse and intestinal histopathological types of Lauren.
  • No significant difference (P < 0.05) was observed between the level of chromosome 8 ploidy and the site, stage or histological type of the adenocarcinomas.
  • C-MYC high amplification, like homogeneously stained regions (HSRs) and double minutes (DMs), was observed only in the intestinal-type.
  • Structural rearrangement of C-MYC, like translocation, was observed only in the diffuse type.
  • In the intestinal-type the C-MYC immunoreactivity was localized only in the nucleus and in the diffuse type in the nucleus and cytoplasm.
  • CONCLUSION: Distinct patterns of alterations between intestinal and diffuse types of gastric tumors support the hypothesis that these types follow different genetic pathways.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 8. Genes, myc. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1998 Nov;107(1):61-4 [9809036.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Exp Mol Pathol. 1999 Jun;66(2):140-8 [10409442.001]
  • [Cites] Exp Mol Pathol. 1999 Jun;66(2):157-62 [10409444.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Braz J Med Biol Res. 2004 Dec;37(12):1831-8 [15558189.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4069-74 [16309200.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):45-9 [16875936.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2909-14 [16886612.001]
  • [Cites] J Korean Med Sci. 1999 Oct;14(5):526-30 [10576148.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):97-103 [10704677.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3139-46 [10955795.001]
  • [Cites] Histopathology. 2000 Sep;37(3):241-9 [10971700.001]
  • [Cites] Histopathology. 2001 Feb;38(2):111-9 [11207824.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):403-6 [11819799.001]
  • [Cites] Arq Gastroenterol. 2001 Oct-Dec;38(4):240-6 [12068534.001]
  • [Cites] Cancer Genet Cytogenet. 2002 May;135(1):23-7 [12072199.001]
  • [Cites] J Cell Mol Med. 2002 Apr-Jun;6(2):151-9 [12169201.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):66-9 [12550762.001]
  • [Cites] Cytopathology. 2003 Feb;14(1):5-11 [12588304.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 2;95(7):E3 [12671026.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1311-20 [13679439.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):155-9 [15015591.001]
  • [Cites] World J Gastroenterol. 2004 Jun 15;10(12):1759-62 [15188501.001]
  • [Cites] Nature. 1983 Nov 10-16;306(5939):194-6 [6646201.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(13):4834-8 [3014513.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Aug;22(4):295-307 [3731046.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Jan;24(1):63-73 [3791173.001]
  • [Cites] Recent Results Cancer Res. 1994;136:179-202 [7863095.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):594-9 [8647618.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Dec;92(2):122-9 [8976368.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):226-32 [9010095.001]
  • [Cites] J Pathol. 1997 Apr;181(4):381-6 [9196434.001]
  • [Cites] Acta Chir Hung. 1997;36(1-4):119-21 [9408311.001]
  • [Cites] J Clin Pathol. 1997 Nov;50(11):896-903 [9462237.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Apr 1;102(1):88-90 [9530349.001]
  • [Cites] Lab Invest. 1998 Sep;78(9):1143-53 [9759658.001]
  • (PMID = 17036397.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088119
  •  go-up   go-down


50. Tominaga K, Kawahara T, Sano T, Toida K, Kuwano Y, Sasaki H, Kawai T, Teshima-Kondo S, Rokutan K: Evidence for cancer-associated expression of NADPH oxidase 1 (Nox1)-based oxidase system in the human stomach. Free Radic Biol Med; 2007 Dec 15;43(12):1627-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PCR of human stomach cDNA libraries showed that Nox1 and Nox organizer 1 (NOXO1) messages were absent from normal stomachs, while they were specifically coexpressed in intestinal- and diffuse-type adenocarcinomas including signet-ring cell carcinoma.
  • In contrast, Nox1 and its partner proteins were expressed in intestinal-type adenocarcinomas (19/21 cases), diffuse-type adenocarcinomas (15/15 cases), and signet-ring cell carcinomas (9/9 cases).
  • Confocal microscopy revealed that Nox1, NOXO1, Nox activator 1, and p22(phox) were predominantly associated with Golgi apparatus in these cancer cells, while diffuse-type adenocarcinomas also contained cancer cells having Nox1 and its partner proteins in their nuclei.
  • [MeSH-minor] Adaptor Proteins, Vesicular Transport / genetics. Adaptor Proteins, Vesicular Transport / metabolism. Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adenoma / enzymology. Adenoma / genetics. Animals. Carcinoma, Signet Ring Cell / enzymology. Carcinoma, Signet Ring Cell / genetics. Free Radicals / metabolism. Gastric Mucosa / enzymology. Gastritis, Atrophic / enzymology. Gastritis, Atrophic / genetics. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Guinea Pigs. Helicobacter Infections / complications. Helicobacter pylori / pathogenicity. Humans. Immunohistochemistry. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18037128.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Vesicular Transport; 0 / Free Radicals; 0 / NOXO1 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.6.3.- / NOX1 protein, human; EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


51. Hong SJ, Kwon KW, Kim SG, Ko BM, Ryu CB, Kim YS, Moon JH, Cho JY, Lee JS, Lee MS, Shim CS, Kim BS: Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine; 2006 Jan 21;33(2):66-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma.
  • We compared the expression patterns of leptin and of the long variant of the leptin receptor (Ob-Rb) between areas with non-ulcerated mucosa and with hyperplastic polyps, adenoma, or adenocarcinoma to evaluate the expression relative to different disease states.
  • Leptin and Ob-Rb were expressed in hyperplastic polyps, adenoma, and adenocarcinoma.
  • In the gastric adenocarcinoma, leptin was expressed significantly less in the poorly differentiated and diffuse-type groups than in the well-differentiated and moderately differentiated groups or in the intestinal type.
  • Based upon our findings, we suggest the possibility that leptin expression can have a pathophysiologic role about the differentiation or growth pattern of gastric adenocarcinoma.
  • A further series of experiments is necessary to elucidate the pathophysiological role of leptin in the differentiation of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Leptin / metabolism. Stomach / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434209.001).
  • [ISSN] 1043-4666
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


52. Chetty R, Serra S, Hsieh E: Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant. Am J Surg Pathol; 2005 Dec;29(12):1668-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant.
  • Two cases of a distinctive variety of basaloid squamous carcinoma (BSC) of the anal canal are described.
  • This appearance together with microcystic spaces simulated that of an adenoid cystic carcinoma.
  • The tumor cells exhibited diffuse nuclear positivity with p63.
  • The eosinophilic basement membrane hyaline material was positive for collagen type IV and also for laminin.
  • The histologic differential diagnosis is true salivary gland-type adenoid cystic carcinoma and basal cell adenocarcinoma.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Basosquamous / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327441.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 50SG953SK6 / Mitomycin; 68238-35-7 / Keratins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


53. Resnick MB, Gavilanez M, Newton E, Konkin T, Bhattacharya B, Britt DE, Sabo E, Moss SF: Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol; 2005 Aug;36(8):886-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue microarrays were created from paraffinized samples from 146 patients with distal gastric adenocarcinomas (61 intestinal and 85 diffuse or mixed subtypes).
  • Moderate to strong staining of claudins 1, 3, 4, and ZO-1 was detected in 74%, 48%, 62%, and 74% of the intestinal but in only 46%, 24%, 45%, and 36% of the diffuse subtype of adenocarcinomas (P < .05).
  • Cox multivariate analysis revealed that tumor stage, diffuse subtype, and moderate to strong claudin 4 staining were associated with decreased survival (P < .02).
  • In conclusion, claudins 1, 3, and 4 and ZO-1 are strongly expressed in most gastric intestinal-type adenocarcinomas but less frequently in diffuse gastric cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112005.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 P20 RR017596-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein
  •  go-up   go-down


54. Mikami Y, Kiyokawa T, Moriya T, Sasano H: Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ('adenoma malignum') and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining. Histopathology; 2005 Feb;46(2):130-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ('adenoma malignum') and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining.
  • AIMS: To define the phenotypic alteration of the stromal component in association with destructive invasion which is a crucial feature in distinguishing minimal deviation adenocarcinoma (MDA) from benign endocervical glandular lesions.
  • METHODS AND RESULTS: We studied endocervical glandular hyperplasias including non-specific-type (NEGH) (n = 3) and lobular-type (LEGH) (n = 8), and minimal deviation adenocarcinoma (MDA) (n = 11), well-differentiated endocervical adenocarcinoma of usual-type (WDA) (n = 11), and adenocarcinoma in situ (AIS) (n = 6) of the cervix, by double immunostaining for oestrogen receptor (ER) and alpha-smooth muscle actin (alpha-SMA) using peroxidase- and alkaline phosphatase-polymer methods, respectively.
  • The distribution of alpha-SMA+ cells was periglandular (6/11), patchy (6/11), and/or diffuse (4/11) in WDA, whereas in MDA it was periglandular (11/11) and/or patchy (8/11).
  • [MeSH-major] Actins / analysis. Adenocarcinoma / pathology. Cervix Uteri / pathology. Receptors, Estrogen / analysis. Uterine Cervical Neoplasms / pathology


55. M A M, Pera G, Agudo A, Bueno-de-Mesquita HB, Palli D, Boeing H, Carneiro F, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Manjer J, Johansson I, Stenling R, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Allen N, Key TJ, Bingham S, Linseisen J, Kaaks R, Overvad K, Jensen M, Olsen A, Tjønneland A, Peeters PH, Numans ME, Ocké MC, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Lund E, Slimani N, Jenab M, Ferrari P, Riboli E, González CA: Cereal fiber intake may reduce risk of gastric adenocarcinomas: the EPIC-EURGAST study. Int J Cancer; 2007 Oct 01;121(7):1618-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was a strong inverse association for diffuse [HR 0.43, 0.22-0.86], but not intestinal type [HR 0.98, 0.54-1.80] tumors.
  • Cereal fiber consumption may help to reduce risk of GC, particularly diffuse type tumors.
  • [MeSH-major] Adenocarcinoma / prevention & control. Dietary Fiber / administration & dosage. Edible Grain. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582605.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105630924
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE: Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev; 2006 Jun 1;20(11):1496-510
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study further the role of these mutations in the initiation and maintenance of lung cancer, we have developed transgenic mice that express an exon 19 deletion mutant (EGFR(DeltaL747-S752)) or the L858R mutant (EGFR(L858R)) in type II pneumocytes under the control of doxycycline.
  • Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.


57. Waguri N, Furukawa K, Shobugawa K, Takizawa K, Ikeda H, Iwamoto Y, Aiba T, Yoneyama O, Igarashi K, Tsukioka S, Yabe M, Kuwabara S, Shibuya H: [A case of gastric cancer with abdominal wall invasion treated by weekly low-dose paclitaxel therapy]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report a case of gastric cancer with diffuse abdominal wall invasion treated with weekly low-dose paclitaxel therapy.
  • Computed tomography revealed diffuse swelling of the abdominal wall and hydronephrosis of the right kidney.
  • Upper gastrointestinal endoscopy demonstrated type 3' advanced gastric cancer.
  • Pathological diagnosis of both gastric tumor and abdominal wall biopsy specimens was poorly-differentiated adenocarcinoma containing signet ring cell carcinoma.
  • Diffuse abdominal wall invasion of gastric cancer like cuirass without ascites is a rare condition, and low-dose paclitaxel was very effective for this condition.
  • [MeSH-major] Abdominal Wall / pathology. Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Signet Ring Cell / pathology. Drug Administration Schedule. Humans. Male. Middle Aged. Neoplasm Invasiveness. Radiography, Abdominal. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912538.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


58. Toki F, Takahashi A, Aihara R, Ogata K, Ando H, Ohno T, Mochiki E, Kuwano H: Relationship between clinicopathological features and mucin phenotypes of advanced gastric adenocarcinoma. World J Gastroenterol; 2010 Jun 14;16(22):2764-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between clinicopathological features and mucin phenotypes of advanced gastric adenocarcinoma.
  • AIM: To investigate a relationship between the clinicopathological features and mucin phenotypes in advanced gastric adenocarcinoma (AGA).
  • METHODS: Immunohistochemical staining was performed to determine the mucin phenotypes in 38 patients with differentiated adenocarcinomas (DACs), 9 with signet-ring cell carcinomas (SIGs), and 48 with other diffuse-type adenocarcinomas (non-SIGs) of AGA.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Signet Ring Cell. Mucins / metabolism. Protein Isoforms / metabolism. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Aug 15;89(4):724-32 [10951333.001]
  • [Cites] World J Gastroenterol. 2007 Jun 21;13(23):3189-98 [17589897.001]
  • [Cites] Pathol Int. 2001 Mar;51(3):165-71 [11328531.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Virchows Arch. 2002 Mar;440(3):304-10 [11889602.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):32-40 [12605364.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Dec;129(12):727-34 [14557879.001]
  • [Cites] Pathol Int. 2004 May;54(5):311-21 [15086835.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1342-8 [15354218.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4866-72 [3015400.001]
  • [Cites] Acta Pathol Jpn. 1986 Sep;36(9):1307-18 [3788560.001]
  • [Cites] Cancer. 1995 Mar 15;75(6 Suppl):1410-7 [7889467.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):103-10 [9293891.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Gastroenterol. 2004 Dec;39(12):1143-9 [15622477.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):454-62 [15609380.001]
  • [Cites] Histopathology. 2005 Oct;47(4):357-67 [16178890.001]
  • [Cites] Gastric Cancer. 2005;8(4):220-7 [16328596.001]
  • [Cites] Scand J Gastroenterol. 2006 Aug;41(8):880-6 [16803685.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] Eur J Histochem. 2006 Oct-Dec;50(4):301-9 [17213039.001]
  • [Cites] Virchows Arch. 2001 Jan;438(1):49-56 [11213835.001]
  • (PMID = 20533596.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 0 / Protein Isoforms
  • [Other-IDs] NLM/ PMC2883132
  •  go-up   go-down


59. Genta RM, Pusztaszeri M: The gastric mucosa in gastric cancer patients in a low-incidence area. Eur J Gastroenterol Hepatol; 2006 Oct;18(10):1085-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Atrophic gastritis, intestinal metaplasia, and pyloric metaplasia are frequent precursors of noncardial intestinal-type gastric adenocarcinoma in populations in which both gastric cancer and Helicobacter pylori infection are common.
  • METHODS: Slides from patients who underwent gastrectomy for adenocarcinoma between 1997 and 2004 were reviewed.
  • Tumors were categorized as intestinal or diffuse; non-neoplastic mucosa was evaluated for gastritis, atrophy, intestinal metaplasia and pyloric metaplasia.
  • Twelve tumors were proximal (all intestinal type), 12 in the corpus (six intestinal-type), and 57 antral (30 intestinal type).
  • Patients with diffuse cancers were younger than those with intestinal type (P<0.05).
  • Nineteen patients (23.4%) had a normal stomach; 30% of T1 tumors and 90% of T4s arose in a normal stomach (P<0.02). H. pylori gastritis was found in 47 patients (58%); they did not differ in age, sex, national origin, cancer location or type from those without gastritis.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Female. Gastrectomy. Gastritis, Atrophic / pathology. Humans. Male. Metaplasia / pathology. Middle Aged. Neoplasm Staging. Pyloric Antrum / pathology. Specimen Handling / methods

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957515.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Sonoda R, Naomoto Y, Shirakawa Y, Fujiwara Y, Yamatsuji T, Noma K, Tanabe S, Takaoka M, Gunduz M, Tsujigiwa H, Nagatsuka H, Ohara N, Yoshino T, Takubo K, Vieth M, Tanaka N: Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma. Histopathology; 2010 Jul;57(1):90-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.
  • AIMS: Metaplastic changes secondary to chronic inflammation at the gastro-oesophageal junction and at the pyloric antrum are recognized as the premalignant conditions of Barrett's oesophageal adenocarcinoma and intestinal-type gastric carcinoma (GC), respectively.
  • Successively, their expression in Barrett's dysplasia was compared with that of GC (22 cases of diffuse-type and 10 of intestinal-type).
  • Interestingly, the expression pattern in Barrett's dysplasia was similar to that in intestinal-type GC, which mainly arises from chronic inflammation.
  • Furthermore, cultured cell lines isolated from differentiated GC tissues, which are often found to be of intestinal-type, revealed up-regulated mRNA expression of HPSE and COX-2.
  • CONCLUSIONS: HPSE and COX-2 are preferentially up-regulated in Barrett's oesophagus and intestinal-type GC.
  • These molecules may play an important role during the development of inflammation-related adenocarcinoma of the upper gastrointestinal tract.
  • [MeSH-major] Adenocarcinoma / enzymology. Barrett Esophagus / enzymology. Cyclooxygenase 2 / metabolism. Esophageal Neoplasms / enzymology. Glucuronidase / metabolism. Stomach Neoplasms / enzymology
  • [MeSH-minor] Base Sequence. Carcinoma in Situ / enzymology. Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Cell Line, Tumor. DNA Primers / genetics. Humans. Microvessels / pathology. Neovascularization, Pathologic. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Up-Regulation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20653782.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


61. Kodama M, Kitadai Y, Sumida T, Ohnishi M, Ohara E, Tanaka M, Shinagawa K, Tanaka S, Yasui W, Chayama K: Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci; 2010 Sep;101(9):1984-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma.
  • Thus, we investigated the relation between PDGF and PDGF receptor (PDGF-R) expression and lymphatic metastasis in human gastric carcinoma.
  • We examined PDGF-B and PDGF-Rβ expression in four human gastric carcinoma cell lines (TMK-1, MKN-1, MKN-45, and KKLS) and in 38 surgical specimens of gastric carcinoma.
  • PDGF-B and PDGF-Rβ expression was examined by immunofluorescence in surgical specimens and in human gastric carcinoma cells (TMK-1) implanted orthotopically in nude mice.
  • PDGF-B and PDGF-Rβ mRNA expression was significantly higher in patients with lymph node metastasis than in those without and was also significantly higher in diffuse-type carcinoma than in intestinal-type carcinoma.
  • Our data indicate that secretion of PDGF-B by gastric carcinoma cells and expression of PDGF-Rβ by tumor-associated stromal cells are associated with lymphatic metastasis.
  • Blockade of PDGF-R signaling pathways may inhibit lymph node metastasis of gastric carcinoma.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Cancer Association.
  • (PMID = 20624165.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-sis; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


62. Kountouras J, Zavos C, Chatzopoulos D: New concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology; 2005 Jul-Aug;52(64):1305-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric cancer not located in the cardia still remains the second most common cancer worldwide, whereas adenocarcinoma of the cardia and gastroesophageal junction has been rapidly rising over the past two decades.
  • Gastric cancer can be subdivided into two distinct pathologic entities, diffuse and intestinal, that have different epidemiologic and prognostic features.
  • Advances have been made in the genetic changes mostly of the intestinal type; its development is probably a multistep process, as has been well described in colon cancer pathogenesis, whereas it remains tentative whether the diffuse type of malignancy follows an analogous progression.
  • E-cadherin/CDH1 gene germline mutations have been recognized in families with an inherited predisposition to gastric cancer of the diffuse type.


63. Kuehn A, Paner GP, Skinnider BF, Cohen C, Datta MW, Young AN, Srigley JR, Amin MB: Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications. Am J Surg Pathol; 2007 Oct;31(10):1528-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromophobe renal cell carcinoma and renal oncocytoma are reported to be variably positive for Ksp-cad with some studies suggesting a discriminatory role for Ksp-cad.
  • Reactivity with Ksp-cad was observed in the following tumors: chromophobe renal cell carcinoma [23/25 (92%), diffuse (>50% of tumor cells)] positivity and membranous characteristically accentuating the "plant cell-like" histomorphology of the typical (clear) type, renal oncocytoma [15/20 (75%), usually diffuse staining with predominantly membranous accentuation], papillary renal cell carcinoma [5/17 (29%) all focal to moderate, eosinophilic type or type 2-3/7 (43%), basophilic type or type 1-2/10 (20%)], Xp11 translocation carcinoma [1/4 (25%), diffuse positivity] and clear cell renal cell carcinoma [6/36 (17%) all focal, clear cell renal cell carcinoma with prominent eosinophilic cells 1/7 (14%)].
  • Immunoreactivity was higher when evaluating whole histologic sections than with tissue microarrays for both chromophobe renal cell carcinoma (100% vs. 60%) and renal oncocytoma (100% vs. 55%).
  • The findings argue against the use of Ksp-cad in differentiating chromophobe renal cell carcinoma and renal oncocytomas and further support their relationship to the distal nephron.
  • Ksp-cad may be helpful in distinguishing these two tumor types from clear cell renal cell carcinoma with prominent eosinophilic cells particularly in cases with limited tissue samples (ie, needle core biopsy).
  • In the similar diagnostic setting, caution must be exercised, however, in differentiating chromophobe renal cell carcinoma and renal oncocytoma from the eosinophilic variant of papillary renal cell carcinoma as moderate expression of Ksp-cad may be observed in papillary renal cell carcinoma.
  • The histogenesis of mucinous tubular and spindle cell carcinoma remains debatable as this tumor does not express Ksp-cad, which is highly expressed normally in the thick ascending loop of Henle and the distal convoluted tubules.
  • In conclusion, Ksp-cad is a useful tumor type associated marker for distinguishing chromophobe renal cell carcinoma and renal oncocytoma from the wide range of nonintercalated cell-related adult renal epithelial neoplasms; addition of this marker to a panel comprised of other histologic subtype-associated markers may greatly facilitate histologic subclassification of adult renal epithelial neoplasms.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cadherins / metabolism. Kidney Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / metabolism. Carcinoma, Transitional Cell / pathology. Eosinophilia / metabolism. Eosinophilia / pathology. Humans. Immunoenzyme Techniques. Immunohistochemistry / methods. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895753.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDH16 protein, human; 0 / Cadherins
  •  go-up   go-down


64. Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF, Takano Y: Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Virchows Arch; 2008 Feb;452(2):147-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric carcinoma cell lines (MKN28, AGS, MKN45, KATO-III and HGC-27) were studied for parafibromin expression by IHC and western blot.
  • Parafibromin expression was localised in the nucleus of gastric epithelial cells, adenoma, carcinoma cells and cell lines.
  • Its expression was gradually decreased from gastritis to gastric carcinoma, through gastric adenomas (p < 0.05) and inversely correlated with tumour size, depth of invasion, lymphatic invasion, lymph node metastasis and Union Internationale Contre le Cancer (UICC) staging (p < 0.05) but not with sex or venous invasion (p > 0.05).
  • Parafibromin was strongly expressed in older carcinoma patients compared with younger ones (p < 0.05).
  • There was stronger positivity of parafibromin in intestinal-type than diffuse-type carcinomas (p < 0.05).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 2003 Sep;40(9):657-63 [12960210.001]
  • [Cites] Pathol Int. 2003 Oct;53(10):659-66 [14516315.001]
  • [Cites] N Engl J Med. 2003 Oct 30;349(18):1722-9 [14585940.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6629-37 [15475453.001]
  • [Cites] Naika. 1967 Nov;20(5):824-9 [4877774.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 1992 Sep-Oct;11(5-6):339-44 [1464819.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):612-20 [15632063.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1272-6 [15580289.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):5052-60 [15923622.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Apr;134(4):481-8 [17876606.001]
  • [Cites] J Med Genet. 2005 Aug;42(8):e51 [16061557.001]
  • [Cites] Horm Metab Res. 2005 Jun;37(6):380-3 [16001331.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Feb;101(2):212-8 [16448924.001]
  • [Cites] Cell. 2006 Apr 21;125(2):327-41 [16630820.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):509-23 [16728578.001]
  • [Cites] Oral Oncol. 2006 Aug;42(7):735-9 [16458039.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1140-9 [16931959.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Nov 10;350(1):17-24 [16989776.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23 [16807756.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1371-8 [17088917.001]
  • [Cites] J Anat. 2006 Dec;209(6):817-27 [17118068.001]
  • [Cites] Mol Cancer Res. 2007 Feb;5(2):183-93 [17314275.001]
  • [Cites] Oncogene. 2007 Feb 22;26(8):1213-21 [16964291.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40 [18091387.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):64-7 [17468290.001]
  • [Cites] Mol Cell. 2003 Jan;11(1):267-74 [12535539.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):676-80 [12434154.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):721-9 [12667454.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6241-8 [16116486.001]
  • (PMID = 18080135.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDC73 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2233709
  •  go-up   go-down


65. Bal N, Yildirim S, Nursal TZ, Bolat F, Kayaselcuk F: Association of ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type. World J Gastroenterol; 2007 Jul 21;13(27):3726-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type.
  • AIM: To investigate the correlation between ezrin expression and types of gastric carcinoma and clinico-pathological variables.
  • METHODS: We examined ezrin protein expression in 75 gastric carcinoma (53 intestinal types of adenocarcinoma, 22 diffuse types of carcinoma) tissues by immunohistochemistry.
  • The results were compared with clinicopathological parameters such as tumor type, grade of tumor, clinical stage, presence of metastatic lymph node, and depth of invasion.
  • RESULTS: Ezrin immunostaining was positive in 43 cases (81.1%) of intestinal type and in 9 (40.9%) cases of diffuse type adenocarcinomas (P < 0.001).
  • CONCLUSION: The low expression of ezrin implicates the loss of adhesion in diffuse carcinomas.
  • Furthermore, overexpression of ezrin in carcinomas with H pylori infection may be a genuine specific pathway in which H pylori may cause/initiate gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Cytoskeletal Proteins / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659733.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / ezrin
  • [Other-IDs] NLM/ PMC4250645
  •  go-up   go-down


66. Mohammad A, Makaju R: Retrospective histopathological analysis of various neoplasms of different parts of the gastrointestinal tract seen at the Kathmandu University Teaching Hospital (KUTH), Dhulikhel, Nepal. Kathmandu Univ Med J (KUMJ); 2006 Oct-Dec;4(4):474-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of these, 3 (16.7%) were of the oesophagus (all squamous cell carcinoma), 10 (55.5%) were of the stomach (six intestinal type and four diffuse type), 2 (11.1%) were of the small intestine (one was lymphoma of the mucosa associated lymphoid tissue--MALTOMA and other was a malignant gastrointestinal stromal tumour--GIST), 3 (16.7%) were of the colorectum (all adenocarcinoma), and none was of the anal canal.
  • CONCLUSION: Relatively large number of cases of the carcinoma of the stomach were found in our this small series of the cases of the gastrointestinal tract in comparison to the Western countries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603957.001).
  • [ISSN] 1812-2078
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


67. Zakharov V, Lin HK, Azzarello J, McMeekin S, Moore KN, Penning TM, Fung KM: Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol; 2010 Jul 05;3(6):608-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.
  • The diagnosis of endometrial hyperplasia and endometrial type adenocarcinoma arising within the uterine cavity has long been rested on morphologic criteria.
  • Although distinction between normal endometrial epithelium from adenocarcinoma is usually straightforward, the separation between normal and hyperplastic endometrium, particularly those cases without atypia, can be a diagnostic challenge.
  • The same is true in separation of hyperplastic endometrium with atypia from endometrial-type endometrial adenocarcinoma.
  • Type 2 3alpha-/type 5 17beta-hydroxysteroid dehydrogenase (HSD) (AKR1C3) is a multifunctional enzyme involved in androgen, estrogen, progesterone, and pros-taglandin metabolism.
  • Its expression has been shown in the epithelium of the renal tubules, urothelial epithelium, and endothelial cells in normal tissues as well as in prostatic adenocarcinoma.
  • We studied the expression of AKR1C3 in 33 endometrial biopsy specimens including 13 cases of normal proliferative endometrium, 8 cases of hyperplastic endometrium with and without atypia, and 12 cases of primary endometrial adenocarcinoma of endometrial type.
  • We demonstrated a uniform, diffuse, and strong expression of AKR1C3 in normal endometrial epithelium but not in endometrial stromal cells.
  • However, reduced AKR1C3 expression cannot distinguish hyperplastic endometrium from endometrial adenocarcinoma of endometrial type.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2004 Jun 22;4:27 [15212687.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):245-9 [12695909.001]
  • [Cites] Lancet. 1991 Aug 3;338(8762):274-7 [1677110.001]
  • [Cites] J Biol Chem. 1993 Jun 15;268(17):12964-9 [8099587.001]
  • [Cites] Biochem J. 1994 Apr 15;299 ( Pt 2):545-52 [8172617.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):491-500 [7856758.001]
  • [Cites] J Biol Chem. 1995 Aug 25;270(34):20162-8 [7650035.001]
  • [Cites] Cell. 1995 Dec 1;83(5):803-12 [8521497.001]
  • [Cites] Biochem J. 1996 Jan 15;313 ( Pt 2):373-6 [8573067.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Nov 12;228(2):474-9 [8920937.001]
  • [Cites] Mol Endocrinol. 1997 Jan;11(1):77-86 [8994190.001]
  • [Cites] Biochem J. 1997 Sep 15;326 ( Pt 3):625-36 [9307009.001]
  • [Cites] Biochem Pharmacol. 1997 Sep 15;54(6):639-47 [9310340.001]
  • [Cites] Mol Endocrinol. 1997 Dec;11(13):1971-84 [9415401.001]
  • [Cites] J Biochem. 1998 Nov;124(5):940-6 [9792917.001]
  • [Cites] Endocrinology. 1999 Feb;140(2):568-74 [9927279.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2177-81 [15284179.001]
  • [Cites] Steroids. 2004 Dec;69(13-14):795-801 [15582534.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):101-7 [15788642.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):701-20 [16322318.001]
  • [Cites] Mol Endocrinol. 2006 Jan;20(1):35-44 [16123151.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2815-25 [16510604.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 27;248(1-2):126-35 [16338060.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 27;248(1-2):136-40 [16406263.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 27;248(1-2):182-91 [16417966.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):169-80 [16601286.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4200-8 [16857792.001]
  • [Cites] BJOG. 2008 Jan;115(1):113-7 [17983420.001]
  • [Cites] Endocr J. 2007 Dec;54(5):667-79 [17785917.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):448-54 [17720776.001]
  • [Cites] J Histochem Cytochem. 2008 Sep;56(9):853-61 [18574251.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3471-7 [18559914.001]
  • [Cites] Mol Cell Endocrinol. 2009 Mar 25;301(1-2):74-82 [18930784.001]
  • [Cites] Int J Clin Exp Pathol. 2009;3(2):147-55 [20126582.001]
  • [Cites] Urology. 2010 Jul;76(1):67-72 [19942269.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3436-43 [11443221.001]
  • [Cites] J Mol Endocrinol. 2000 Feb;24(1):135-44 [10657005.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):67-77 [10998348.001]
  • [Cites] Am J Obstet Gynecol. 2001 Feb;184(3):303-8 [11228478.001]
  • [Cites] Mol Endocrinol. 2001 Dec;15(12):2093-105 [11731611.001]
  • [Cites] Chem Biol Interact. 2003 Feb 1;143-144:621-31 [12604248.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Mar;40(3):367-72 [234975.001]
  • (PMID = 20661409.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES013508; United States / NCI NIH HHS / CA / R01 CA090744; United States / NCI NIH HHS / CA / 1R01-CA90744; United States / NIEHS NIH HHS / ES / P30-ES013508
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; EC 1.1.1.- / AKR1C3 protein, human; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases
  • [Other-IDs] NLM/ PMC2907123
  • [Keywords] NOTNLM ; Aldo-keto reductase / endomtrial cancer / estrogen / progesterone / prostaglandin
  •  go-up   go-down


68. Horn LC, Hänel C, Bartholdt E, Dietel J: Serous carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature indicate the existence of 2 prognostically relevant tumor types. Int J Gynecol Pathol; 2006 Jul;25(3):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature indicate the existence of 2 prognostically relevant tumor types.
  • We report a serous carcinoma of the endometrium with a choriocarcinomatous component and review of the literature.
  • A 61-year-old woman underwent hysterectomy and bilateral salpingo-oophorectomy for a serous carcinoma with choriocarcinomatous component.
  • Postoperatively, the patient developed diffuse pulmonary metastatic disease.
  • The second type presents as an endometrial carcinoma with single syncytiotrophoblast-like cells, associated with low serum hCG, no distant metastatic disease, and, consequently, a better prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Choriocarcinoma / pathology. Endometrial Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810062.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  • [Number-of-references] 14
  •  go-up   go-down


69. Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH: Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol; 2007 Oct;14(10):2748-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma.
  • However, the role of CD24 in gastric adenocarcinoma remains largely unknown.
  • METHODS: The expression pattern of CD24 in 103 gastric adenocarcinomas (31 diffuse type, 60 intestinal type, and 12 mixed type) was analyzed by immunohistochemistry.
  • RESULTS: Cytoplasmic CD24 expression occurred in 50% of the gastric adenocarcinoma patients and was associated with high-stage tumor (Stage III-IV, P = .023), serosal invasion (SI, P = .010), lymphovascular invasion (LVI, P = .039), and lower 10-year survival (P = .0238).
  • The CD24 staining pattern was different in intestinal and diffuse-type gastric adenocarcinomas.
  • Further analysis showed that cytoplasmic CD24 expression was, in fact, correlated with high-stage tumor, SI, LVI, and lower 10-year survival significantly (P = .020, P = .007, P = .018, P = .0285, respectively) in diffuse-type gastric adenocarcinoma.
  • Moreover, multivariate analysis showed that cytoplasmic CD24 expression was an independent risk factor of SI and LVI respectively (P = .0083 and P = .0019), and thus it contributed to high-stage tumor and poor patient survival in diffuse- or mixed-type gastric adenocarcinoma.
  • CONCLUSIONS: Cytoplasmic expression of CD24 was associated with invasiveness and poorer prognosis and can serve as a novel target for prognostic prediction and adjuvant treatment of patients with diffuse-type gastric adenocarcinoma after tumor resection.
  • [MeSH-major] Adenocarcinoma / pathology. Antigens, CD24 / analysis. Biomarkers, Tumor / analysis. Cytoplasm / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680316.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor
  •  go-up   go-down


70. Pineda-Daboin K, Neto A, Ochoa-Perez V, Luna MA: Nasopharyngeal adenocarcinomas: a clinicopathologic study of 44 cases including immunohistochemical features of 18 papillary phenotypes. Ann Diagn Pathol; 2006 Aug;10(4):215-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 28 salivary gland type, 13 conventional low-grade papillary NPACs of surface origin, and 3 metastatic adenocarcinomas, 2 thyroid and 1 lung.
  • Two of the low-grade papillary NPACs simulated thyroid carcinoma; they expressed CK7, CK19, and TTF-1 but were negative for thyroglobulin.
  • Polymorphous low-grade papillary NPACs expressed diffuse reactivity to S-100, whereas low-grade papillary NPACs were negative or focally positive.
  • In contrast, 18 (64.2%) of the 28 patients with salivary gland-type NPACs had died of the disease or were living with disease at follow-up.
  • Primary NPACs can be classified by their morphology and clinical behavior into 2 groups: surface origin type and salivary gland type.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Immunoenzyme Techniques / methods. Nasopharyngeal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844563.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


71. Pianzola HM, Ottino A: ["Glassy - cell" like adenocarcinoma: a new variant of gastric tumor]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ["Glassy - cell" like adenocarcinoma: a new variant of gastric tumor].
  • [Transliterated title] Adenocarcinoma de tipo glassy - cell: una nueva variante de tumor gástrico.
  • Most gastric malignancies correspond histologically to adenocarcinomas, either of the intestinal or diffuse type, other tumoral varieties being much less frequent.
  • We report a case of a malignant epithelial tumor, whose histological and cytological characteristics correspond to an unusual, although well defined entity, which may appear in the cervix and less frequently in the endometrium, known as adenocarcinoma of the glassy - cell variety.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225449.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


72. Alipov G, Nakayama T, Nakashima M, Wen CY, Niino D, Kondo H, Pruglo Y, Sekine I: Epstein-Barr virus-associated gastric carcinoma in Kazakhstan. World J Gastroenterol; 2005 Jan 7;11(1):27-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated gastric carcinoma in Kazakhstan.
  • The incidence of the diffuse type of EBV-GC was significantly higher in Kazakhstan (14%, 13/91) than that of the intestinal type (2%, 1/48).
  • CONCLUSION: Geographical differences in the incidence of EBV-GC may reflect the epidemiologic factors and/or dietary habits independent of histological type and sex.
  • [MeSH-major] Adenocarcinoma, Mucinous / ethnology. Carcinoma, Signet Ring Cell / ethnology. Epstein-Barr Virus Infections / ethnology. Herpesvirus 4, Human / isolation & purification. Stomach Neoplasms / ethnology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609391.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC4205378
  •  go-up   go-down


73. Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, Calvieri A, Pizzagalli F, Graziano N, Ferraro E, Lorino G, Altomare A, Magnani M, Graziano F, Tonini G: Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol; 2008 Dec;154(3):360-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes.
  • In the subgroup of patients with intestinal-type gastric cancer, a significant risk of gastric cancer was associated with TLR-4 Thr399Ile genotype (P = 0.006).
  • [MeSH-major] Adenocarcinoma / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics. Toll-Like Receptor 4 / genetics

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2006 Jul 1;177(1):322-32 [16785528.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):244-52 [18176606.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):187-91 [10835634.001]
  • [Cites] Biotechniques. 2001 Jul;31(1):22-4 [11464514.001]
  • [Cites] Genome Biol. 2002 Jul 29;3(8):REVIEWS3011 [12186654.001]
  • [Cites] Crit Care. 2003 Feb;7(1):23-38 [12617738.001]
  • [Cites] J Exp Med. 2003 Jun 16;197(12):1787-91 [12796470.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32552-60 [12807870.001]
  • [Cites] Scand J Infect Dis. 2003;35(9):555-62 [14620134.001]
  • [Cites] Nagoya J Med Sci. 2003 Nov;66(3-4):103-17 [14727687.001]
  • [Cites] Clin Exp Immunol. 2004 Jun;136(3):521-6 [15147355.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):499-511 [15229469.001]
  • [Cites] Nat Immunol. 2004 Oct;5(10):975-9 [15454920.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 6;97(7):525-32 [15812078.001]
  • [Cites] Cytokine. 2005 Jun 7;30(5):264-8 [15927851.001]
  • [Cites] Nat Rev Immunol. 2005 Jun;5(6):446-58 [15928677.001]
  • [Cites] Nat Rev Immunol. 2006 Jan;6(1):9-20 [16493424.001]
  • [Cites] Inflamm Bowel Dis. 2006 Jul;12(7):641-50 [16804402.001]
  • [Cites] Dig Dis Sci. 2007 Jan;52(1):254-61 [17171451.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):352-5 [17301271.001]
  • [Cites] J Commun Dis. 2006 Mar;38(3):230-45 [17373355.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(2):281-97 [17382277.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):905-12 [17324405.001]
  • [Cites] Trends Pharmacol Sci. 2007 Apr;28(4):162-5 [17331592.001]
  • [Cites] BMC Cancer. 2007;7:70 [17462092.001]
  • [Cites] Hum Immunol. 2007 Nov;68(11):901-7 [18082569.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • (PMID = 18826495.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / TLR4 protein, human; 0 / Toll-Like Receptor 4
  • [Other-IDs] NLM/ PMC2633233
  •  go-up   go-down


74. Huang KH, Chen JH, Wu CW, Lo SS, Hsieh MC, Li AF, Lui WY: Factors affecting recurrence in node-negative advanced gastric cancer. J Gastroenterol Hepatol; 2009 Sep;24(9):1522-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Prognostic factors of lymph node-negative gastric adenocarcinoma after curative resection have been discussed.
  • METHODS: Recurrent sites and correlated clinicopathological factors of 372 patients with lymph node-negative advanced gastric adenocarcinoma that underwent R0 resection from 1988 to 2005 were analyzed.
  • Recurrent rates according to site of recurrence were 26 peritoneal seeding (51.0%), 26 locoregional (51.0%), 17 hematogenous (33.3%), and 4 lymph node metastasis (7.8%).
  • Clinicopathological factors to predict peritoneal seeding were serosal exposure, lymphovascular invasion, Lauren's diffuse type differentiation and scirrhous stromal reaction.
  • Serosal exposure, tumor size, microscopic infiltrating growth type predicts locoregional recurrence.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Gastrectomy. Hematologic Neoplasms / pathology. Neoplasm Recurrence, Local. Neoplasm Seeding. Stomach Neoplasms / secondary. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol Hepatol. 2009 Sep;24(9):1478-9 [19743992.001]
  • (PMID = 19467143.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


75. Lynch HT, Grady W, Suriano G, Huntsman D: Gastric cancer: new genetic developments. J Surg Oncol; 2005 Jun 1;90(3):114-33; discussion 133
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) an intestinal type and 2) a diffuse type.
  • The intestinal type is more common in the general population, more likely to be sporadic and related to environmental factors such as diet, particularly salted fish and meat as well as smoked foods, cigarette smoking, and alcohol use.
  • On the other hand, the diffuse type is more likely to have a primary genetic etiology, a subset of which, known as hereditary diffuse gastric cancer (HDGC), is due to the E-cadherin (CDH1) germline mutation.
  • The diffuse type pathology is characterized by poorly cohesive clusters of cells which infiltrate the gastric wall, leading to its widespread thickening and rigidity of the gastric wall, known as linitis plastica.
  • Helicobacter pylori infection is associated with risk for both the intestinal and diffuse varieties of gastric cancer.
  • Germline truncating mutations of the CDH1 gene, which codes for the E-cadherin protein, were initially identified in three Maori families from New Zealand that were predisposed to diffuse GC.
  • Beta-catenin and gamma-catenin compete for the same binding site on the E-cadherin cytoplasmic tail, directly linking the adhesion complex to the cytoskeleton through alpha-catenin.
  • Beta-catenin gene (CTNNB1) mutations have been described predominantly in intestinal-type gastric cancers and CTNNB1 gene amplification and overexpression have recently been described in a mixed-type gastric cancer.
  • This paper reviews the genetics of both intestinal and diffuse types of gastric carcinoma, their differential diagnosis, molecular genetics, pathology, and, when known, their mode of genetic transmission within families.
  • [MeSH-minor] Adenocarcinoma / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / surgery. Cytoskeletal Proteins / genetics. Female. Gastrectomy. Gastrointestinal Stromal Tumors / genetics. Genetic Counseling. Genetic Testing. Helicobacter Infections / complications. Helicobacter pylori. Humans. Male. Pedigree. Risk. Smoking / adverse effects. Trans-Activators / genetics. beta Catenin

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15895459.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1U01 CA86389
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


76. Trajkov D, Stardelova K, Dimitrova M, Mishevski J, Serafimoski V: Helicobacter pylori and gastric carcinoma. Prilozi; 2007 Dec;28(2):39-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori and gastric carcinoma.
  • The aim of the study was to evaluate the relation of Helicobacter pylori (HP) infection and gastric cancer and a possible relation with a certain histopathological type of gastric cancer and localization within the stomach.
  • The patients were divided into 2 groups (HP positive and HP negative) and additionally, depending on histopathological type, into intestinal, diffuse and cardia cancer, and localization as cardia carcinoma, proximal and distal carcinoma.
  • There were 36 intestinal type of gastric cancer, 34 (94.4%) HP positive (statistically significant), 19 patients with diffuse type, and 8 (42.1%) HP positive.
  • The remaining 5 were carcinoma of cardia and all were HP negative.
  • This study confirmed the high incidence of HP infection in patients with gastric carcinoma, particularly in those with an intestinal type of cancer.
  • Carcinomas were predominantly localized in the distal part of the stomach, especially in the HP positive group of intestinal type.


77. Vang R, Vinh TN, Burks RT, Barner R, Kurman RJ, Ronnett BM: Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma. Int J Gynecol Pathol; 2005 Oct;24(4):391-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma.
  • We report three cases of unusual tubal-type endocervical glandular proliferations simulating minimal deviation adenocarcinoma in women with a history of in utero diethylstilbestrol (DES) exposure.
  • The glandular epithelium displayed extensive tubal-type differentiation in all cases.
  • Immunohistochemical studies showed diffuse expression of estrogen and progesterone receptors and essentially no expression of p16 in two cases tested; there was no expression of CD10 in one case that was tested.
  • The proliferations lacked features of mucinous and tubo-endometrioid types of minimal deviation adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Cervix Uteri / pathology. Diethylstilbestrol / adverse effects. Uterine Cervical Neoplasms

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175088.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


78. Capellá G, Pera G, Sala N, Agudo A, Rico F, Del Giudicce G, Plebani M, Palli D, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Berrino F, Vineis P, Tumino R, Panico S, Berglund G, Simán H, Nyrén O, Hallmans G, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key T, Bingham S, Caldas C, Linseisen J, Nagel G, Overvad K, Tjonneland A, Boshuizen HC, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, Kaaks R, Riboli E, González CA: DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. Int J Epidemiol; 2008 Dec;37(6):1316-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study.
  • However, ERCC2 K751Q polymorphism was associated with an increased risk for non-cardial neoplasm [odds ratio (OR) = 1.78; 95% confidence interval (CI) 1.02-3.12], being ERCC2 K751Q and D312N polymorphisms associated with the diffuse type.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Repair / genetics. Gastritis, Atrophic / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641418.001).
  • [ISSN] 1464-3685
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Biomarkers; 9001-10-9 / Pepsinogen A; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


79. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ: PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol; 2010 Feb;34(2):137-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
  • The differential diagnosis of exuberant mesonephric hyperplasia includes minimal deviation adenocarcinoma of the cervix, a tumor with deceptively bland morphology for which no reliable diagnostic biomarkers currently exist.
  • PAX2 encodes a transcription factor necessary in the development of the Wolffian duct system, and the protein is expressed in several tumors of mesonephric origin, including renal cell carcinoma, Wilm tumor, and nephrogenic adenoma.
  • We hypothesized that PAX2 may also be expressed in mesonephric lesions of the cervix and may distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma of the cervix.
  • We demonstrated that PAX2 was strongly and diffusely expressed in mesonephric remnants (6 of 6) and in mesonephric hyperplasia (18 of 18); however, no expression was noted in mesonephric adenocarcinoma (0 of 1).
  • In contrast, only 2 cases of endocervical adenocarcinoma were positive for PAX2 [invasive adenocarcinoma of the minimal deviation type (0 of 5), usual type (1 of 22), and endometrioid type (1 of 1)].
  • Adjacent adenocarcinoma in situ, as well as cases of pure adenocarcinoma in situ (0 of 6), were also PAX2 negative.
  • These results suggest that PAX2 immunoreactivity may be useful to (1) distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma, (2) to distinguish lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma, and (3) to distinguish endocervical tubal metaplasia or cervical endometriosis from endocervical adenocarcinoma in situ.
  • Overall, a strong, diffuse nuclear PAX2 expression pattern in a cervical glandular proliferation predicts a benign diagnosis (positive predictive value 90%, negative predictive value 98%; P<0.001); however, PAX2 should not be interpreted in isolation from the architectural and cytologic features of the lesion as it may be expressed in some stage II endometrial adenocarcinomas involving the cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Cervix Uteri / pathology. Mesonephros / pathology. Mullerian Ducts / pathology. PAX2 Transcription Factor / metabolism. Uterine Cervical Neoplasms / diagnosis


80. Lee LY, Wu CM, Wang CC, Yu JS, Liang Y, Huang KH, Lo CH, Hwang TL: Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to claudin-4 expression. Histol Histopathol; 2008 05;23(5):515-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Matrix metalloproteinases (MMPs) MMP-2 and MMP-9 can degrade type IV collagen of extracellular matrix and basal membranes.
  • We found that all of MMP-2, MMP-9 and claudin-4 expressions were significantly higher in intestinal-type than in diffuse-type gastric cancer.
  • The results showed that MMP-2, MMP-9 and claudin-4 expression may be phenotypic features, distinguishing intestinal-type and diffuse-type gastric cancer.
  • Possibly, claudin-4 played a role in determining MMP-9 activity which favored intestinal-type gastric cancer to distal metastasis.
  • [MeSH-major] Adenocarcinoma / metabolism. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Membrane Proteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283635.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN4 protein, human; 0 / Claudin-4; 0 / Membrane Proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


81. Bancel B, Esteve J, Souquet JC, Toyokuni S, Ohshima H, Pignatelli B: Differences in oxidative stress dependence between gastric adenocarcinoma subtypes. World J Gastroenterol; 2006 Feb 21;12(7):1005-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in oxidative stress dependence between gastric adenocarcinoma subtypes.
  • RESULTS: Tumor cells staining for iNOS, NTYR and 8-OH-dG were detected in 41%, 62% and 50% of infiltrative carcinoma, respectively.
  • The three markers were shown for the first time in intraepithelial carcinoma.
  • The expression of iNOS was significantly more frequent in tubular carcinoma (TC) compared to diffuse carcinoma (DC) (54% vs 18%; P = 0.008) or in polymorphous carcinoma (PolyC) (54% vs 21%; P = 0.04).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Oxidative Stress. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Carcinoma in Situ / chemistry. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. DNA, Neoplasm / metabolism. Deoxyguanine Nucleotides / analysis. Female. Gastric Mucosa / chemistry. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Nitric Oxide / metabolism. Nitric Oxide Synthase Type II / metabolism. Precancerous Conditions / chemistry. Precancerous Conditions / pathology. Precancerous Conditions / physiopathology. Retrospective Studies. Tyrosine / analogs & derivatives. Tyrosine / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 1993 Apr;101(4):330-6 [7686760.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 30;187(3):1291-7 [1384469.001]
  • [Cites] Int J Cancer. 1994 Sep 15;58(6):825-9 [7523311.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):184-90 [10646872.001]
  • [Cites] Cancer Lett. 1999 Nov 15;146(2):173-80 [10656623.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):167-76 [10680883.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1394-400 [10778969.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):144-55 [10881024.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Helicobacter. 2001 Mar;6(1):37-43 [11328364.001]
  • [Cites] Dig Dis Sci. 2001 Apr;46(4):836-44 [11330421.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1325-32 [11350902.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1758-66 [11419826.001]
  • [Cites] Cancer Lett. 2001 Oct 30;172(2):177-85 [11566494.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):591-5 [12174362.001]
  • [Cites] BMC Cancer. 2002 Apr 29;2:8 [11978184.001]
  • [Cites] Helicobacter. 2002 Dec;7(6):342-8 [12485120.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1296-301 [12763220.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 1;417(1):3-11 [12921773.001]
  • [Cites] J Clin Pathol. 2003 Sep;56(9):699-702 [12944556.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):806-12 [14984945.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1279-82 [8640814.001]
  • [Cites] Am J Surg Pathol. 1996;20 Suppl 1:S8-22 [8694148.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3238-43 [8764115.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Invest Dermatol. 1996 Nov;107(5):733-7 [8875958.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):365-74 [9121119.001]
  • [Cites] FEBS Lett. 1997 Jul 14;411(2-3):157-60 [9271196.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19633-6 [9289489.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1841-5 [9328184.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92(10):1853-7 [9382051.001]
  • [Cites] Mutat Res. 1997 Dec;387(3):147-63 [9439711.001]
  • [Cites] Cancer Lett. 1998 Mar 13;125(1-2):61-8 [9566697.001]
  • [Cites] Gut. 1998 Mar;42(3):351-6 [9577340.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):702-9 [9670827.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:25-36 [9701002.001]
  • [Cites] Eur J Cancer Prev. 1998 Dec;7(6):439-47 [9926291.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1411-5 [10389926.001]
  • [Cites] Free Radic Biol Med. 1999 Aug;27(3-4):401-10 [10468215.001]
  • [Cites] Cancer Lett. 1999 Oct 1;144(2):161-7 [10529016.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1918-22 [15222037.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2232-40 [15259072.001]
  • [Cites] Food Chem Toxicol. 1990 Sep;28(9):647-52 [2272563.001]
  • [Cites] Gut. 1994 Feb;35(2):179-85 [8307467.001]
  • (PMID = 16534838.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Neoplasm; 0 / Deoxyguanine Nucleotides; 0 / Neoplasm Proteins; 31C4KY9ESH / Nitric Oxide; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4087889
  •  go-up   go-down


82. Ohno T, Yokoyama Y, Aihara R, Mochiki E, Asao T, Kuwano H: Sudden bilateral sensorineural hearing loss as the presenting symptom of meningeal carcinomatosis of gastric cancer: report of a case. Surg Today; 2010 Jun;40(6):561-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningeal carcinomatosis is the diffuse infiltration of the meninges by metastatic carcinoma.
  • Upper gastrointestinal endoscopy revealed a large type 3 gastric cancer, and the pathological diagnosis was poorly differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Hearing Loss, Bilateral / etiology. Hearing Loss, Sensorineural / etiology. Hearing Loss, Sudden / etiology. Meningeal Carcinomatosis / secondary. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Sensorineural hearing loss.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Otol. 1992 Jul;13(4):369-71 [1415503.001]
  • [Cites] Br J Cancer. 2006 Dec 18;95(12):1642-7 [17133268.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1655-62 [3309199.001]
  • [Cites] J Clin Neurosci. 2005 Apr;12(3):315-8 [15851093.001]
  • [Cites] Brain Nerve. 2007 Dec;59(12):1385-9 [18095490.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):517-27 [12057097.001]
  • [Cites] N Engl J Med. 1973 Oct 11;289(15):770-3 [4517004.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Jan;106(1):92-7 [1734379.001]
  • [Cites] J R Coll Surg Edinb. 1998 Apr;43(2):119-21 [9621540.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):68-73 [3079822.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Arch Neurol. 1996 Jul;53(7):626-32 [8929170.001]
  • [Cites] Arch Neurol. 1974 Feb;30(2):122-37 [4405841.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 May;124(5):592-4 [11337674.001]
  • [Cites] Cancer Treat Rev. 1999 Apr;25(2):103-19 [10395835.001]
  • [Cites] Surg Today. 2008;38(12):1102-7 [19039635.001]
  • [Cites] Neurol Sci. 2005 Feb;25(6):345-7 [15729499.001]
  • [Cites] Surg Today. 2008;38(5):445-8 [18560969.001]
  • (PMID = 20496139.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


83. Zamecnik M, Voltr L, Stuk J, Chlumska A: Krukenberg tumor with yolk sac tumor differentiation. Int J Gynecol Pathol; 2008 Apr;27(2):223-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumor was in the gastric antrum, and it showed morphology of poorly differentiated adenocarcinoma with diffuse and solid growth pattern.
  • In the ovarian metastases, YST element showed microcystic/reticular and solid patterns, whereas the adenocarcinoma component was of diffuse type with signet ring cells and with some undifferentiated areas.
  • The case represents further example of the somatic cell-derived tumor with focal germ cell-type differentiation and the first report of YST differentiation in Krukenberg tumor.

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317220.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


84. Chin K, Fujimura M, Sekit N, Mikami K, Kamijima S, Suzuki H, Ichikawa T: [Case of malignant lymphoma of the prostate complicated with prostate adenocarcinoma]. Nihon Hinyokika Gakkai Zasshi; 2009 Nov;100(7):698-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of malignant lymphoma of the prostate complicated with prostate adenocarcinoma].
  • Esophagogastroduodenoscopy revealed a huge ulcer in the stomach, and based on biopsy findings, he was pathologically diagnosed as having diffuse large B-cell type malignant lymphoma.
  • Histological findings revealed diffuse large B-cell type malignant lymphoma and moderately differentiated adenocarcinoma of the prostate.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasms, Multiple Primary. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999135.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 12
  •  go-up   go-down


85. Fan Z, Li J, Dong B, Huang X: Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin Cancer Res; 2005 Sep 1;11(17):6162-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis.
  • PURPOSE: This study was designed to (a) analyze the correlation between the expression of Cdx2 and Hep and the clinicopathologic features of patients with gastric carcinoma, and (b) determine the value of combined analysis of Cdx2 and Hep expression in distinguishing histologic types and prognoses of gastric carcinomas.
  • EXPERIMENTAL DESIGN: The expression of Cdx2 and Hep were studied using immunohistochemistry of paraffin-embedded tumor specimens from 109 patients who underwent D2 resection for gastric adenocarcinoma from 1995 to 1998.
  • RESULTS: Nuclear Cdx2 and Hep expression was detected in 36.7% (40 of 109) and 54.1% (59 of 109) of gastric carcinoma cases, respectively.
  • Expression of Cdx2 and Hep was significantly higher in intestinal-type carcinomas than in diffuse-type carcinomas (P = 0.027 and P = 0.037, respectively).
  • Multivariate analysis revealed that the expression of Cdx2 and Hep were independent prognostic indicators of gastric carcinoma.
  • The combination of Cdx2 and Hep expression was significantly lower in diffuse-type carcinoma than in intestinal or mixed-type carcinoma.
  • Multivariate analysis revealed that Cdx2 and Hep expression was an independent prognostic indicator of gastric carcinoma (P < 0.001).
  • CONCLUSIONS: These data suggest that combined analysis of Cdx2 and Hep has significant value in distinguishing histologic types and in predicting the prognosis of gastric carcinoma.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16144916.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


86. Sargan I, Motoc A, Vaida MA, Bolintineanu S, Vîscu S: Anatomic and pathological aspects in the pathology of malignant gastric tumors. Rom J Morphol Embryol; 2006;47(2):163-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most gastric carcinomas are adenocarcinoma, 404 (90%) cases--could be classified as follows: 167 cases of tubular adenocarcinoma; 39 cases of papillary adenocarcinoma; 24 cases of mucinous or colloid adenocarcinoma; 141 "signet ring"-cell carcinoma; 33 cases of undifferentiated carcinoma.
  • Currently there is an increase of the incidence of the "diffuse"-type in women and at younger ages.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Biopsy. Female. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106525.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


87. Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg; 2006 Oct;93(10):1270-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: CRS combined with PIC was associated with improved survival in patients with less extensive previous surgery and diffuse peritoneal adenomucinosis histopathological type.
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / mortality. Peritoneal Neoplasms / mortality. Pseudomyxoma Peritonei / mortality

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838392.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


88. Albores-Saavedra J, Simpson K, Dancer YJ, Hruban R: Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann Diagn Pathol; 2007 Feb;11(1):3-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas.
  • These pancreatic carcinomas of intestinal type represented 10% of 110 consecutively removed ductal carcinomas of the pancreas.
  • All intestinal type carcinomas expressed cytokeratin 7, carcinoembryonic antigen, CDX2, and MUC2.
  • The pattern of reactivity of cytokeratin 7 and carcinoembryonic antigen was diffuse, whereas that of mucin 2 staining and CDX2 nuclear labeling was focal and confined predominantly to goblet cells and less frequently to columnar cells.
  • Five carcinomas were associated with high-grade pancreatic intraepithelial neoplasia of intestinal type.
  • More studies are needed to determine the biologic behavior of this distinctive histologic variant of ductal adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Ductal / pathology. Intestinal Neoplasms / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240300.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Homeodomain Proteins; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


89. Xu WQ, Song LJ, Liu Q, Zhao L, Zheng L, Yan ZW, Fu GH: Expression of anion exchanger 1 is associated with tumor progress in human gastric cancer. J Cancer Res Clin Oncol; 2009 Oct;135(10):1323-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study is to determine the potential clinical implications of AE1 expression in gastric carcinoma.
  • The expression of AE1 in normal and malignant tissues from 286 patients with early and advanced gastric carcinoma was examined.
  • Positive immunostaining of AE1 was detected in gastric carcinoma regardless of the location.
  • AE1 was most frequently expressed in the gastric antrum carcinoma compared with gastric body cancer (P = 0.034).
  • In para-cancer tissues of intestinal-type gastric cancer, the expression frequency of AE1 was higher than that in diffuse-type (P = 0.011).
  • [MeSH-major] Adenocarcinoma / metabolism. Anion Exchange Protein 1, Erythrocyte / metabolism. Biomarkers, Tumor / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Oncol. 2008 Mar;30(1):81-7 [18438347.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] Int Rev Cytol. 1990;123:177-99 [2289848.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2655-63 [18442100.001]
  • [Cites] Exp Oncol. 2008 Jun;30(2):112-6 [18566573.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):651-74 [16997151.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3540-8 [18441088.001]
  • [Cites] J Clin Gastroenterol. 2008 Jan;42(1):36-41 [18097287.001]
  • [Cites] FEBS Lett. 2005 Apr 11;579(10):2105-10 [15811326.001]
  • [Cites] Gastric Cancer. 2005;8(4):238-44 [16328598.001]
  • [Cites] J Physiol Pharmacol. 2007 Nov;58 Suppl 5(Pt 1):371-8 [18204149.001]
  • [Cites] J Gastroenterol. 2002;37 Suppl 13:39-44 [12109664.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1727-38 [18431520.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Aug;20(8):1266-78 [16048577.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30531-9 [15123620.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 May;292(5):C1759-67 [17251326.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1628-31 [18431518.001]
  • [Cites] Biochemistry. 1993 Jul 27;32(29):7413-20 [8338838.001]
  • [Cites] Curr Opin Hematol. 2008 May;15(3):184-90 [18391782.001]
  • [Cites] Lancet. 2008 Aug 2;372(9636):392-7 [18675689.001]
  • [Cites] Biochemistry. 1995 Mar 21;34(11):3588-95 [7893655.001]
  • [Cites] J Biol Chem. 1990 Jan 5;265(1):462-71 [2294114.001]
  • [Cites] Exp Physiol. 2006 Jan;91(1):153-61 [16239253.001]
  • [Cites] Neoplasia. 2007 Oct;9(10):812-9 [17971901.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2008 Jul;18(3):513-22, ix [18674700.001]
  • [Cites] J Cell Sci. 2006 Sep 1;119(Pt 17):3602-12 [16912075.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):488 [17325494.001]
  • [Cites] Cell. 1989 Dec 1;59(5):927-37 [2686841.001]
  • [Cites] Mol Membr Biol. 1997 Oct-Dec;14(4):155-65 [9491367.001]
  • [Cites] J Nephrol. 2002 Mar-Apr;15 Suppl 5:S41-53 [12027221.001]
  • [Cites] Pflugers Arch. 2007 Jun;454(3):373-84 [17492309.001]
  • [Cites] Scand J Clin Lab Invest. 2006;66(7):607-21 [17101553.001]
  • [Cites] Biochemistry. 2008 Apr 15;47(15):4510-7 [18358003.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2227-35 [18381965.001]
  • (PMID = 19330352.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Biomarkers, Tumor
  •  go-up   go-down


90. Herrera-Goepfert R, Akiba S, Koriyama C, Ding S, Reyes E, Itoh T, Minakami Y, Eizuru Y: Epstein-Barr virus-associated gastric carcinoma: Evidence of age-dependence among a Mexican population. World J Gastroenterol; 2005 Oct 21;11(39):6096-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated gastric carcinoma: Evidence of age-dependence among a Mexican population.
  • AIM: To investigate features of Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC) among a Mexican population.
  • METHODS: Cases of primary gastric adenocarcinoma were retrieved from the files of the Departments of Pathology at the Instituto Nacional de Cancerologia and the Instituto Nacional de la Nutricion in Mexico City.
  • The anatomic site of the gastric neoplasia was identified, and carcinomas were histologically classified as intestinal and diffuse types and subclassified as proposed by the Japanese Research Society for Gastric Cancer.
  • Age and histological type showed statistically significant differences, when EBER-1-positive and -negative gastric carcinomas were compared.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273633.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4436624
  •  go-up   go-down


91. Satoh A, Shuto K, Okazumi S, Ohira G, Natsume T, Hayano K, Narushima K, Saito H, Ohta T, Nabeya Y, Yanagawa N, Matsubara H: Role of perfusion CT in assessing tumor blood flow and malignancy level of gastric cancer. Dig Surg; 2010;27(4):253-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases with Lauren's diffuse type carcinoma were found to have decreased blood flow compared to the mixed or intestinal type.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20668380.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


92. Da MX, Wu XT, Guo TK, Zhao ZG, Luo T, Qian K, Zhang MM, Wang J: Clinical significance of telomerase activity in peritoneal lavage fluid from patients with gastric cancer and its relationship with cellular proliferation. World J Gastroenterol; 2007 Jun 14;13(22):3122-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proliferating cell nuclear antigen (PCNA) in gastric carcinoma was immunohistochemically examined.
  • The positive rate of telomerase activity was significantly higher than that of PLC in the group of pT(4) (15/16 vs 9/16, P < 0.05), P(1-3) (13/13 vs 9/13, P < 0.05) and diffuse type (22/42 vs 13/42, P < 0.05).
  • [MeSH-major] Adenocarcinoma / diagnosis. Cell Proliferation. Peritoneal Neoplasms / diagnosis. Stomach Neoplasms / pathology. Telomerase / metabolism


93. Seifert M, Welter C, Mehraein Y, Seitz G: Expression of the nm23 homologues nm23-H4, nm23-H6, and nm23-H7 in human gastric and colon cancer. J Pathol; 2005 Apr;205(5):623-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, by immunohistochemical analysis, nm23-H4 and -H6 overexpression correlated with the intestinal tumour type in gastric cancer tissues, whereas no increased immunoreactivity for the three nm23 proteins was noted in the diffuse type tumour specimens.
  • These findings indicate that nm23-H6, and particularly nm23-H4 and -H7, may be involved in the development of colon and gastric carcinoma, the latter possibly in a type-specific manner.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Nucleoside-Diphosphate Kinase / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726650.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NM23 Nucleoside Diphosphate Kinases; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / NME4 protein, human; EC 2.7.4.6 / Nucleoside Diphosphate Kinase D; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  •  go-up   go-down


94. Huerta JM, Navarro C, Chirlaque MD, Tormo MJ, Steindorf K, Buckland G, Carneiro F, Johnsen NF, Overvad K, Stegger J, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Boeing H, Kaaks R, Rohrmann S, Vigl M, Lagiou P, Trichopoulos D, Trichopoulou A, Bas Bueno-de-Mesquita H, Monninkhof EM, Numans ME, Peeters PH, Mattiello A, Pala V, Palli D, Tumino R, Vineis P, Agudo A, Ardanaz E, Arriola L, Molina-Montes E, Rodríguez L, Lindkvist B, Manjer J, Stenling R, Lund E, Crowe FL, Key TJ, Khaw KT, Wareham NJ, Jenab M, Norat T, Romaguera D, Riboli E, González CA: Prospective study of physical activity and risk of primary adenocarcinomas of the oesophagus and stomach in the EPIC (European Prospective Investigation into Cancer and nutrition) cohort. Cancer Causes Control; 2010 May;21(5):657-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyse the association between types of physical activity (occupational, recreational and household, vigorous and overall) and risk of primary oesophageal (OAC) or gastric adenocarcinoma (GAC).
  • Analyses were repeated by tumour site (cardia/non-cardia) and histological type (intestinal/diffuse).
  • No association was found for any type of PA and risk of cardia cancers of the stomach.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Exercise. Health Behavior. Nutrition Surveys. Stomach Neoplasms / epidemiology


95. Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T: Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res; 2008 May 15;14(10):3022-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
  • PURPOSE: Expression levels of insulin-like growth factor type 1 receptor (IGF-IR), epidermal growth factor receptor (EGFR), and HER2 expressions have been linked to clinical outcomes in several solid tumors.
  • Multivariate survival analysis showed that IGF-IR-positive expression [hazard ratio (HR) 2.14, 95% confidence interval (95% CI) 1.20-3.82; P = 0.01], performance status 1 or 2 (HR 1.83, 95% CI 1.15-2.91; P = 0.01), and diffuse type tumors (HR 1.71; 95% CI 1.08-2.70; P = 0.02) were significant predictors of poor survival.
  • CONCLUSIONS: IGF-IR expression in surgical GC specimens, poor performance status, and diffuse type tumors are significant predictors of poor outcomes in patients with GC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis. Receptor, IGF Type 1 / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Gene Expression. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483367.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


96. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, Hirakawa K, Ouchi Y, Nishiyama N, Kataoka K, Miyazono K: Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A; 2007 Feb 27;104(9):3460-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we present an application of a short-acting, small-molecule TGF-beta type I receptor (TbetaR-I) inhibitor at a low dose in treating several experimental intractable solid tumors, including pancreatic adenocarcinoma and diffuse-type gastric cancer, characterized by hypovascularity and thick fibrosis in tumor microenvironments.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2003 Jun;9(6):713-25 [12778170.001]
  • [Cites] J Drug Target. 2002 Nov;10(7):539-48 [12683721.001]
  • [Cites] J Med Chem. 2003 Sep 11;46(19):3953-6 [12954047.001]
  • [Cites] J Cell Biol. 2003 Dec 22;163(6):1303-11 [14676305.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8977-83 [14695216.001]
  • [Cites] Lancet Oncol. 2004 Sep;5(9):541-9 [15337483.001]
  • [Cites] Technol Cancer Res Treat. 2004 Oct;3(5):451-7 [15453810.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 [2946403.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 1989;6(3):193-210 [2692843.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):43-54 [8521616.001]
  • [Cites] Pancreas. 1996 Nov;13(4):395-400 [8899800.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] J Cell Biol. 1998 May 4;141(3):805-14 [9566978.001]
  • [Cites] Gynecol Oncol. 1998 Sep;70(3):351-7 [9790787.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Science. 1999 May 28;284(5419):1534-7 [10348742.001]
  • [Cites] Nat Rev Drug Discov. 2004 Dec;3(12):1011-22 [15573100.001]
  • [Cites] Bioconjug Chem. 2005 Jan-Feb;16(1):122-30 [15656583.001]
  • [Cites] Cardiovasc Res. 2005 Feb 15;65(3):599-608 [15664386.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):161-71 [15738981.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1240-6 [15785749.001]
  • [Cites] J Gastroenterol. 2005 May;40(5):518-25 [15942718.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3759-68 [16105884.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:659-93 [16212511.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):335-44 [16507830.001]
  • [Cites] Clin Med Res. 2006 Mar;4(1):66-78 [16595794.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6714-21 [16818646.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):688-701 [16900224.001]
  • [Cites] Dev Biol. 2000 Jan 1;217(1):42-53 [10625534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2626-31 [10716993.001]
  • [Cites] Nat Genet. 2000 Nov;26(3):328-31 [11062473.001]
  • [Cites] Curr Oncol Rep. 2001 Mar;3(2):156-62 [11177748.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 23;47(1):113-31 [11251249.001]
  • [Cites] EMBO J. 2001 Apr 2;20(7):1663-73 [11285230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • (PMID = 17307870.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ly-364947; 0 / Pyrazoles; 0 / Pyrroles; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC1800736
  •  go-up   go-down


97.